Tri-Tech Holding, long known as a leading developer of sophisticated turn-key sewage treatment/odor control solutions for some of China’s top municipalities/cities and wielder of an impressive portfolio of intellectual property (2 patents, 27 software copyrights to date), announced that affiliate Beijing Satellite Science & Technology Co., Ltd. (BSST) has secured a $1.87M public bid with the Yanchang Petroleum Group to provide operational/security TV monitoring at a new industrial park in Shaanxi.
The Jingbian Energy and Chemical Industrial Park in Jingbian County, currently under development by Yanchang, will be comprised of a total of six petroleum refining/post-processing plants, collectively capable of yielding million of tons per year of high-value intermediate petroleum products.
TRIT affiliate BSST has been tasked with the essential mission of providing comprehensive CCTV infrastructure, in order to ensure that production security is maintained. The approach outlined by BSST will take the form of a two-pronged systems implementation, with one prong handling production/operational concerns and the other covering perimeter security.
A huge job and a huge boon for BSST, who will provide everything from the design, to materials and implementation/operator commissioning, leveraging the Company’s vast experience in system integration and project installations to deliver by a projected completion date of May, 2013.
CEO of TRIT, Warren Zhao, applauding this second production safety project secured by BSST through Yanchang, spoke of the exemplary progress made thus far with the initial Yanchang project, asserting that the work prompted Yanchang to engage BSST for additional help. Zhao noted that the initial Yanchang project was on schedule for Oct. 2011 completion and pointed to a broadening international focus at TRIT, briefly mentioning ongoing industrial wastewater treatment opportunities being pursued in North America via their Wisconsin-based, J&Y Water Division.
Zhao also pointed to ongoing business development efforts in the Middle East and India, assuring investors that the Company would offer timely press releases concerning prevailing developments with such active bids.
President of TRIT, Gavin Cheng, echoed his colleague’s sentiments roundly and went into greater detail on the industrial CCTV system to be utilized, highlighting in particular the powerful fusion of long range imaging technology and environmental sensors. Cheng underscored the operational benefits of such a system that can detect equipment malfunctions in order to prevent accidents, as well as monitoring production continuously, enabling spills or leakages to be identified and handle if they do occur before the situation gets any worse. Cheng emphasized the importance of such a system to the overall secure operation and performance of the industrial park, and pledged to maintain strict oversight.
For more information on the project, or to find out more about Tri-Tech Holding Inc., please visit the Company’s website at: www.Tri-Tech.cn
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Friday, September 30, 2011
Horizon Pharma, Inc. (HZNP) Appoints Grey and Pauli to Board of Directors
Located in Northbrook, Illinois, Horizon Pharma is a biopharmaceutical company that commercializes innovative medicine that targets the unmet therapeutic needs in arthritis, pain and inflammatory diseases. Today, Horizon took another step forward with the announcement they have appointed industry veterans Michael Grey and Ronald Pauli to their Board of Directors.
Michael Grey received his bachelor’s degree in chemistry from the University of Nottingham in the United Kingdom. Since then, Grey has had an impressive career. Grey currently serves as president and chief executive officer at Lumena Pharmaceuticals, Inc. In a career that has spanned more than 3 decades, he has held senior positions at a number of other companies, including president and chief executive officer of SGX Pharmaceuticals, Inc. (sold to Eli Lilly in 2008), president and chief executive officer of Trega Biosciences, Inc. (sold to Lion Bioscience in 2001) and president of BioChem Therapeutic Inc.
Ronald Pauli received a bachelor’s degree in accounting from Michigan State University and went on to earn a master’s degree in finance from Walsh College. Pauli has led an illustrious career and is currently chief business officer at Sagent Pharmaceuticals, Inc., where he was recently promoted from his role as chief financial officer. As CFO, he played a key role in Sagent’s recent initial public offering. In addition, Mr. Pauli has held senior positions at a number of biopharmaceutical companies, including chief financial officer at NeoPharm, Inc. and corporate controller and interim chief financial officer at Abraxis BioScience, Inc., formerly American Pharmaceutical Partners, Inc. Mr. Pauli previously served as corporate controller for Applied Power, Inc. and R.P. Scherer Corporation and also held multiple finance positions at Kmart Corporation.
The appointments of Grey and Pauli come on the heels of Dr. Peter Johann resigning from the Horizon Board of Director’s after an impactful career with the company.
Leading the way at Horizon is Timothy P. Walbert whom serves as the Chairman, President and CEO of the Company. Walbert stated, “We are pleased to welcome Mike and Ron to our board. Their extensive pharma and biopharmaceutical experience in business development, finance and building companies will be an asset to our Board and beneficial to Horizon’s future growth.”
In reference to the resignation of Dr. Johann, Walbert commented, “On behalf of the Board of Directors of Horizon, I would like to thank Peter for his contributions to the Company’s journey to date and we wish him well in his endeavors.”
Currently, Horizon Pharma, Inc. is trading in the $7.48 range. To learn more about the company as a whole, visit their corporate website at: www.horizonpharma.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Michael Grey received his bachelor’s degree in chemistry from the University of Nottingham in the United Kingdom. Since then, Grey has had an impressive career. Grey currently serves as president and chief executive officer at Lumena Pharmaceuticals, Inc. In a career that has spanned more than 3 decades, he has held senior positions at a number of other companies, including president and chief executive officer of SGX Pharmaceuticals, Inc. (sold to Eli Lilly in 2008), president and chief executive officer of Trega Biosciences, Inc. (sold to Lion Bioscience in 2001) and president of BioChem Therapeutic Inc.
Ronald Pauli received a bachelor’s degree in accounting from Michigan State University and went on to earn a master’s degree in finance from Walsh College. Pauli has led an illustrious career and is currently chief business officer at Sagent Pharmaceuticals, Inc., where he was recently promoted from his role as chief financial officer. As CFO, he played a key role in Sagent’s recent initial public offering. In addition, Mr. Pauli has held senior positions at a number of biopharmaceutical companies, including chief financial officer at NeoPharm, Inc. and corporate controller and interim chief financial officer at Abraxis BioScience, Inc., formerly American Pharmaceutical Partners, Inc. Mr. Pauli previously served as corporate controller for Applied Power, Inc. and R.P. Scherer Corporation and also held multiple finance positions at Kmart Corporation.
The appointments of Grey and Pauli come on the heels of Dr. Peter Johann resigning from the Horizon Board of Director’s after an impactful career with the company.
Leading the way at Horizon is Timothy P. Walbert whom serves as the Chairman, President and CEO of the Company. Walbert stated, “We are pleased to welcome Mike and Ron to our board. Their extensive pharma and biopharmaceutical experience in business development, finance and building companies will be an asset to our Board and beneficial to Horizon’s future growth.”
In reference to the resignation of Dr. Johann, Walbert commented, “On behalf of the Board of Directors of Horizon, I would like to thank Peter for his contributions to the Company’s journey to date and we wish him well in his endeavors.”
Currently, Horizon Pharma, Inc. is trading in the $7.48 range. To learn more about the company as a whole, visit their corporate website at: www.horizonpharma.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Midas Medici Group Holdings, Inc. (MMED) Aims for Senior U.S. Exchange
Midas Medici, a green-oriented IT solutions provider, announced today that it is actively seeking a listing on a senior U.S. stock exchange (NASDAQ or AMEX), once the company meets all applicable listing requirements. The move is meant to increase the company’s visibility in U.S. capital markets, and is a key part of their overall high-growth strategy.
Midas CEO and co-founder, Mr. Nana Baffour, commented on the announcement. “Graduating to a senior U.S. exchange is a high priority for Midas given the tremendous progress we have made growing our business through a combination of organic growth and accretive acquisitions in the United States and Brazil. Midas’ management team and our board of directors are confident that a senior listing will be of tremendous benefit to existing and potential shareholders. Not only would we expect a senior exchange listing to allow us to attract additional investors and increase liquidity, it would also make Midas available to a broader segment of the institutional community as we strive to make further improvements to our revenue, and enhance shareholder value.”
Midas supplies companies and institutions with virtualization, cloud computing, and data management solutions. The company helps optimize IT and data center investments, reducing data loss and cutting energy use, and also works with utilities in the U.S. and Brazil to improve the efficiency of the electric grid through the application of digital technologies.
Midas serves a diverse list of more than 700 clients, from mid-sized to Fortune 1000 companies. Midas’ comprehensive green IT and Smart Grid solutions are provided to customers around the world, including Pepsi, HP, Oracle, PBS, AT&T, Oracle, National Grid, the International Monetary Fund, and many more. The company’s stated mission is to become a leading global provider of green IT and Smart Grid solutions.
For more information on Midas Medici, please visit: www.MidasMedici.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Midas CEO and co-founder, Mr. Nana Baffour, commented on the announcement. “Graduating to a senior U.S. exchange is a high priority for Midas given the tremendous progress we have made growing our business through a combination of organic growth and accretive acquisitions in the United States and Brazil. Midas’ management team and our board of directors are confident that a senior listing will be of tremendous benefit to existing and potential shareholders. Not only would we expect a senior exchange listing to allow us to attract additional investors and increase liquidity, it would also make Midas available to a broader segment of the institutional community as we strive to make further improvements to our revenue, and enhance shareholder value.”
Midas supplies companies and institutions with virtualization, cloud computing, and data management solutions. The company helps optimize IT and data center investments, reducing data loss and cutting energy use, and also works with utilities in the U.S. and Brazil to improve the efficiency of the electric grid through the application of digital technologies.
Midas serves a diverse list of more than 700 clients, from mid-sized to Fortune 1000 companies. Midas’ comprehensive green IT and Smart Grid solutions are provided to customers around the world, including Pepsi, HP, Oracle, PBS, AT&T, Oracle, National Grid, the International Monetary Fund, and many more. The company’s stated mission is to become a leading global provider of green IT and Smart Grid solutions.
For more information on Midas Medici, please visit: www.MidasMedici.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Thursday, September 29, 2011
Scorpex, Inc. (SRPX) Moves Forward with Initiative to Become Fully Reporting; Engages Audit Firm
Scorpex, Inc., an emerging leader of industrial, hazardous and toxic waste disposal services in the Baja Mexico/California region, today announced the engagement of Mantyla McReynolds, a CPA firm based in Salt Lake City, Utah, as its audit firm. An audit from Mantyla McReynolds will allow the Company to file financial reports with the U.S. Securities and Exchange Commission (“SEC”) pursuant to the Securities Exchange Act of 1934 and increase transparency for both current and future investors.
As previously reported, Scorpex engaged the services of the Acadia Group to prepare for its audit and the filing of financial reports with the SEC. According to today’s release, the Acadia Group is working with Mantyla McReynolds to complete the audit as planned during the fourth quarter of this year.
Chief Executive Officer Joseph Caywood stated, “We are pleased to announce the Mantyla McReynolds engagement and look forward to completing the audit. Becoming fully reporting with the SEC is our goal, and engaging Mantyla McReynolds is a priority and significant milestone for our business.”
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
As previously reported, Scorpex engaged the services of the Acadia Group to prepare for its audit and the filing of financial reports with the SEC. According to today’s release, the Acadia Group is working with Mantyla McReynolds to complete the audit as planned during the fourth quarter of this year.
Chief Executive Officer Joseph Caywood stated, “We are pleased to announce the Mantyla McReynolds engagement and look forward to completing the audit. Becoming fully reporting with the SEC is our goal, and engaging Mantyla McReynolds is a priority and significant milestone for our business.”
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
China Precision Steel, Inc. (CPSL) Reports Strong Increase in Sales
China Precision Steel, Inc. reported higher year over year sales in the fourth quarter of fiscal 2011, as the company benefited from strong demand for many of its product lines.
China Precision Steel reported sales of $46 million in the quarter ending June 30, 2011. This was a 27% year over year increase from the corresponding quarter of 2010, and a 46% sequential increase from the third quarter of fiscal 2011.
China Precision Steel volume also showed a sharp year over year increase, with sales of 49,104 tons in the most recent quarter. This was a 26% increase over the 39,112 tons sold in the fourth quarter of fiscal 2010.
China Precision Steel attributed the better results to strong demand for the company’s cold-rolled steel products. The company manufactures and sells low carbon cold-rolled steel for applications in the home appliance and packaging industries, and high carbon cold-rolled steel for use in the automotive industry.
China Precision Steel said that sales of these two types of products now account for 93% of company sales, down from 98% in the same quarter in fiscal 2010. The company ended the quarter with a $25.6 million backlog of orders.
For more information on the company, go to www.chinaprecisionsteelinc.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
China Precision Steel reported sales of $46 million in the quarter ending June 30, 2011. This was a 27% year over year increase from the corresponding quarter of 2010, and a 46% sequential increase from the third quarter of fiscal 2011.
China Precision Steel volume also showed a sharp year over year increase, with sales of 49,104 tons in the most recent quarter. This was a 26% increase over the 39,112 tons sold in the fourth quarter of fiscal 2010.
China Precision Steel attributed the better results to strong demand for the company’s cold-rolled steel products. The company manufactures and sells low carbon cold-rolled steel for applications in the home appliance and packaging industries, and high carbon cold-rolled steel for use in the automotive industry.
China Precision Steel said that sales of these two types of products now account for 93% of company sales, down from 98% in the same quarter in fiscal 2010. The company ended the quarter with a $25.6 million backlog of orders.
For more information on the company, go to www.chinaprecisionsteelinc.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Wednesday, September 28, 2011
YM BioSciences, Inc. (YMI) Begins Phase II Trial for Its CYT387 Drug
YM BioSciences Inc. is a drug development company. It is currently advancing three clinical stage products: CYT387, a small molecule, dual inhibitor of the JAK1/JAK2 kinases; CYT997, a vascular disrupting agent; and nimotuzumab, an EGFR-targeting monoclonal antibody.
The company today announced that it has enrolled the first of 60 patients in its Phase II trial of CYT387. The drug is to be administered twice daily for the treatment of myelofibrosis. The trial is intended to further evaluate the safety and tolerability of YM BioScienes’ JAK1/JAK2 inhibitor, as well as its efficacy in reducing spleen size, improving symptoms and reducing transfusion dependence in patients with the disease.
In an ongoing Phase I/II trial, CYT387 appears to have a favorable safety profile and has produced a clinically beneficial response in a number of patients. Initial data from this new trial will be used to further enhance YM BioSciences’ pivotal trial designs. The company will acquire additional safety and efficacy data for the drug at doses complementary to those evaluated in the ongoing 166 patient trial.
YM BioSciences’ president and CEO, Dr. Nick Glover, added, “The substantial volume of patient data from the combined studies will be an important component of any future marketing application.”
For more information on YM BioSciences and its CYT387 drug, please visit the company’s website at www.ymbiosciences.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The company today announced that it has enrolled the first of 60 patients in its Phase II trial of CYT387. The drug is to be administered twice daily for the treatment of myelofibrosis. The trial is intended to further evaluate the safety and tolerability of YM BioScienes’ JAK1/JAK2 inhibitor, as well as its efficacy in reducing spleen size, improving symptoms and reducing transfusion dependence in patients with the disease.
In an ongoing Phase I/II trial, CYT387 appears to have a favorable safety profile and has produced a clinically beneficial response in a number of patients. Initial data from this new trial will be used to further enhance YM BioSciences’ pivotal trial designs. The company will acquire additional safety and efficacy data for the drug at doses complementary to those evaluated in the ongoing 166 patient trial.
YM BioSciences’ president and CEO, Dr. Nick Glover, added, “The substantial volume of patient data from the combined studies will be an important component of any future marketing application.”
For more information on YM BioSciences and its CYT387 drug, please visit the company’s website at www.ymbiosciences.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Sky Power Solutions Corp. (SPOW) Announces Qualification of Sky Power System for French Government Incentives
Sky Power Solutions Corp., a company that engages in developing rechargeable lithium-ion batteries for power production in the United States, has recently announced that its Sky Power system has qualified for incentives from the French Government for solar, renewable energy installation.
Consumers who install the Sky Power system in France can get a 50% government tax credit, potential eligibility for a grant, a loan free of interest, and a possible modest tax- free annual income. A “tax credit” means that, even though you may not pay an income tax in France, the French government will provide you with a sum equivalent to that in cash.
All of this is resulting from a major drive by the French government to raise the amount of renewable energy that is produced each year to comply with EU objectives.
The resale of electricity into the electric grid in France from photovoltaic solar panels has been made available to homeowners since 2006, although until recently the income realized from it was subject to income tax. Provided that the power that is produced does not exceed 3kwh, the income that is received is no longer charged with income tax. The amount of income that could potentially be generated each year is EUR 1500/ EUR 2000 for a 3KW system. “The French government has provided great incentives for homeowners who install the Sky Power system making the time to recover the cost of the unit very short, meaning your Sky Power system becomes a source of extra tax fee income,” says Rich Ralston, PR and Media Manager for Sky Power Solutions.
France utilizes Feed-in-Tariffs for the rates that solar users are paid for the electric power that they sell to the grid. The rates range from: EUR 0.34 to EUR 0.58/KWh, all depending on how the system is integrated. Feed-in-Tariff rates are much higher than the rate that electric power is sold by the utility to residential customers.
The Sky Power system is being developed at the R&D facilities of Li-ion Motors Corp., utilizing the same team that has led the winning 2010 X-Prize for Li-ion Motors in a side-by-side competition by reaching an impressive 187MPGe with their WAVE II fully electric car. Taking advantage of the lessons learned in the development process of one of the most efficient cars to date, Sky Power Solutions has harnessed the mind power to further develop Sky Power, Stand Alone, Residential, Solar Concentrating, Electric Generation system.
The Sky Power Solutions residential solar power station will potentially be able to reduce the average user’s monthly electric grid consumption by up to 30-40% with ZERO emissions and ZERO carbon footprint; utilizing only the Sun’s power. With immense visual appeal, the Sky Power Solutions system can be very easily installed in most backyards, taking up less than one-third of the space that conventional Solar panels take up. The entry-level price point for a Sky Power Solutions-Concentrated Solar electric system has been estimated to be $5,000 at its release. Numerous units can be combined for increased capacity and the amount of electricity that is sold to the grid.
For more information on Sky Power Solutions Corp., visit their website at http://www.skypowersolutions.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Consumers who install the Sky Power system in France can get a 50% government tax credit, potential eligibility for a grant, a loan free of interest, and a possible modest tax- free annual income. A “tax credit” means that, even though you may not pay an income tax in France, the French government will provide you with a sum equivalent to that in cash.
All of this is resulting from a major drive by the French government to raise the amount of renewable energy that is produced each year to comply with EU objectives.
The resale of electricity into the electric grid in France from photovoltaic solar panels has been made available to homeowners since 2006, although until recently the income realized from it was subject to income tax. Provided that the power that is produced does not exceed 3kwh, the income that is received is no longer charged with income tax. The amount of income that could potentially be generated each year is EUR 1500/ EUR 2000 for a 3KW system. “The French government has provided great incentives for homeowners who install the Sky Power system making the time to recover the cost of the unit very short, meaning your Sky Power system becomes a source of extra tax fee income,” says Rich Ralston, PR and Media Manager for Sky Power Solutions.
France utilizes Feed-in-Tariffs for the rates that solar users are paid for the electric power that they sell to the grid. The rates range from: EUR 0.34 to EUR 0.58/KWh, all depending on how the system is integrated. Feed-in-Tariff rates are much higher than the rate that electric power is sold by the utility to residential customers.
The Sky Power system is being developed at the R&D facilities of Li-ion Motors Corp., utilizing the same team that has led the winning 2010 X-Prize for Li-ion Motors in a side-by-side competition by reaching an impressive 187MPGe with their WAVE II fully electric car. Taking advantage of the lessons learned in the development process of one of the most efficient cars to date, Sky Power Solutions has harnessed the mind power to further develop Sky Power, Stand Alone, Residential, Solar Concentrating, Electric Generation system.
The Sky Power Solutions residential solar power station will potentially be able to reduce the average user’s monthly electric grid consumption by up to 30-40% with ZERO emissions and ZERO carbon footprint; utilizing only the Sun’s power. With immense visual appeal, the Sky Power Solutions system can be very easily installed in most backyards, taking up less than one-third of the space that conventional Solar panels take up. The entry-level price point for a Sky Power Solutions-Concentrated Solar electric system has been estimated to be $5,000 at its release. Numerous units can be combined for increased capacity and the amount of electricity that is sold to the grid.
For more information on Sky Power Solutions Corp., visit their website at http://www.skypowersolutions.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Onyx Service & Solutions, Inc. (ONYX) Set to Build First Diesel-Reduction Solar Project in Honduras with $84 Million Contract
Onyx Service and Solutions, Inc., a global company committed to designing cutting edge energy technology, products, manufacturing advances and construction projects to successfully compete in a global energy marketplace, announced that after a presentation last Wednesday at the Roatan Municipal Government Chambers it is confident that their first major solar power project will be in Honduras. The 18.5 megawatt solar project will earn Onyx $84 million and will allow it to use 65,000 of its branded 280 watt solar panels. Onyx will use this power plant as the entree for the company into a lucrative market of nations that solely use diesel produced electricity for their energy needs.
Honduras is a great first location as a US ally with a huge expat population trying to free itself from the clutches of Venezuela and the influence of Hugo Chavez. Presently, the island of Roatan relies 100% on diesel produced electricity. With diesel prices constantly rising, this total reliance is hurting both the tourist industry and the ability of the nation to attract new businesses. As a top rated retirement location in the world, a fixed cost for energy is an essential attraction. Solar power is a solution to one of the area’s biggest problems.
The next steps for Onyx include the completion of the agreement with the project investors and initiation of the regulatory processes. Onyx has already identified ten-acre tracts that are located in areas with the appropriate exposure to the sun, close to the existing electrical grid and with construction access. The project will be completed in thirds so each tract can be acquired in stages. Each of the stages is expected to utilize 23,500 panels at 280 watts each.
For more information on the Company, please visit www.OnyxService.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Honduras is a great first location as a US ally with a huge expat population trying to free itself from the clutches of Venezuela and the influence of Hugo Chavez. Presently, the island of Roatan relies 100% on diesel produced electricity. With diesel prices constantly rising, this total reliance is hurting both the tourist industry and the ability of the nation to attract new businesses. As a top rated retirement location in the world, a fixed cost for energy is an essential attraction. Solar power is a solution to one of the area’s biggest problems.
The next steps for Onyx include the completion of the agreement with the project investors and initiation of the regulatory processes. Onyx has already identified ten-acre tracts that are located in areas with the appropriate exposure to the sun, close to the existing electrical grid and with construction access. The project will be completed in thirds so each tract can be acquired in stages. Each of the stages is expected to utilize 23,500 panels at 280 watts each.
For more information on the Company, please visit www.OnyxService.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
VistaGen Therapeutics, Inc. (VSTA) Announces Expansion of Key Stem Cell Technology Patent Estate Supporting Its Drug Rescue and Cell Therapy Programs
VistaGen Therapeutics, Inc., a biotechnology company applying stem cell technology for drug rescue and cell therapy, was pleased to announce today the issuance of two additional United States patents supporting its therapeutic and drug discovery programs.
U.S. Patent 7,763,466, titled “Mesoderm and Definitive Endoderm Cell Populations,” and U.S. Patent 7,955,849, titled “Method of Enriching a Mammalian Cell Population for Mesoderm Cells,” further enhance VistaGen’s intellectual property portfolio and provide additional protection for its proprietary research and development activities. Methods covered in these important new U.S. patents describe the use of activin and serum-free culture conditions for producing endoderm and mesoderm.
“Strong and enforceable intellectual property rights are critical components of our plan to optimize the commercial potential of our Human Clinical Trials in a Test Tube™ platform,” said Shawn K. Singh, VistaGen’s Chief Executive Officer. “These patents further solidify our growing IP portfolio. Generally speaking, they expand the application of our activin-driven pluripotent stem cell differentiation technology to include a broader range of tissues and organ systems, and significantly strengthen our market position.”
Mesoderm and endoderm are two of the three primary early precursors, “germ layers,” which develop into all of the non-neuronal cells of the body. Endoderm is the innermost of the three primary developmental germ layers, and develops into the gastrointestinal tract, including the major cells of the liver and pancreas, respiratory tracts of the lungs, other endocrine glands and organs, such as the thyroid and thymus glands, the major cells of the kidney and the auditory and urinary systems. Mesoderm is the germ layer lying adjacent to the endoderm. These multi-potential cells develop into cardiac and skeletal muscles, all the cells of blood and lymphatic systems, bone, cartilage, fat, the lining of blood vessels, and connective tissues.
Activins are members of the important transforming growth factor beta (TGF-beta) family of “morphogens,” i.e. developmental factors that direct and control the differentiation and eventual fate of early precursor cells. During development, the body uses differing concentrations of morphogens, similar to activin, to direct precursors to become the various mature cells discussed above. Methods utilizing differing concentrations of activin to direct and control the differentiation of various mature cell types are described in these issued U.S. patents and are widely-believed as having significant commercial value.
In addition to the patent estate that VistaGen owns and controls by license in the U.S., the Company has proprietary rights to a large and growing number of patents granted in territories outside the U.S. Having recently reported its original research demonstrating the use of pluripotent stem cells to generate insulin, these issued U.S. patents further highlight VistaGen’s leadership position in the field as the Company applies its Human Clinical Trials in a Test Tube™ platform for proprietary applications in drug rescue, cell therapy and regenerative medicine.
The patent families related to these two issued patents are subject to exclusive licenses to VistaGen on a worldwide basis through an agreement with Mount Sinai School of Medicine (MSSM) in New York. The patents stem from work conducted by scientists in the laboratory of Dr. Gordon Keller, formerly a Professor of Gene and Cell Medicine at MSSM and Director of its Black Family Stem Cell Institute. Dr. Keller is now Director of the University Health Network’s McEwen Centre for Regenerative Medicine in Toronto and Chairman of VistaGen’s Scientific Advisory Board.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
U.S. Patent 7,763,466, titled “Mesoderm and Definitive Endoderm Cell Populations,” and U.S. Patent 7,955,849, titled “Method of Enriching a Mammalian Cell Population for Mesoderm Cells,” further enhance VistaGen’s intellectual property portfolio and provide additional protection for its proprietary research and development activities. Methods covered in these important new U.S. patents describe the use of activin and serum-free culture conditions for producing endoderm and mesoderm.
“Strong and enforceable intellectual property rights are critical components of our plan to optimize the commercial potential of our Human Clinical Trials in a Test Tube™ platform,” said Shawn K. Singh, VistaGen’s Chief Executive Officer. “These patents further solidify our growing IP portfolio. Generally speaking, they expand the application of our activin-driven pluripotent stem cell differentiation technology to include a broader range of tissues and organ systems, and significantly strengthen our market position.”
Mesoderm and endoderm are two of the three primary early precursors, “germ layers,” which develop into all of the non-neuronal cells of the body. Endoderm is the innermost of the three primary developmental germ layers, and develops into the gastrointestinal tract, including the major cells of the liver and pancreas, respiratory tracts of the lungs, other endocrine glands and organs, such as the thyroid and thymus glands, the major cells of the kidney and the auditory and urinary systems. Mesoderm is the germ layer lying adjacent to the endoderm. These multi-potential cells develop into cardiac and skeletal muscles, all the cells of blood and lymphatic systems, bone, cartilage, fat, the lining of blood vessels, and connective tissues.
Activins are members of the important transforming growth factor beta (TGF-beta) family of “morphogens,” i.e. developmental factors that direct and control the differentiation and eventual fate of early precursor cells. During development, the body uses differing concentrations of morphogens, similar to activin, to direct precursors to become the various mature cells discussed above. Methods utilizing differing concentrations of activin to direct and control the differentiation of various mature cell types are described in these issued U.S. patents and are widely-believed as having significant commercial value.
In addition to the patent estate that VistaGen owns and controls by license in the U.S., the Company has proprietary rights to a large and growing number of patents granted in territories outside the U.S. Having recently reported its original research demonstrating the use of pluripotent stem cells to generate insulin, these issued U.S. patents further highlight VistaGen’s leadership position in the field as the Company applies its Human Clinical Trials in a Test Tube™ platform for proprietary applications in drug rescue, cell therapy and regenerative medicine.
The patent families related to these two issued patents are subject to exclusive licenses to VistaGen on a worldwide basis through an agreement with Mount Sinai School of Medicine (MSSM) in New York. The patents stem from work conducted by scientists in the laboratory of Dr. Gordon Keller, formerly a Professor of Gene and Cell Medicine at MSSM and Director of its Black Family Stem Cell Institute. Dr. Keller is now Director of the University Health Network’s McEwen Centre for Regenerative Medicine in Toronto and Chairman of VistaGen’s Scientific Advisory Board.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Tuesday, September 27, 2011
Codexis, Inc. (CDXS) Secures Foothold in Brazilian First Generation Ethanol
Codexis, industrial biotech developer of products which make manufacturing cleaner and more efficient, in conjunction with Raizen Energia S.A., a $12B JV esteemed as Brazil’s largest sugar and ethanol producer, announced signage of a joint development agreement to develop an enhanced first generation ethanol process, shrewdly exploiting Raizen’s solid footprint as the top sugar/ethanol producer in Brazil.
The agreement will see the Codexis CodeEvolver™ platform implemented in order to upgrade the existing process utilized by Raizen for manufacturing ethanol from sugar cane. Pilot production at Raizen’s Bonfim mill will look to accelerate the some 600M gallons of ethanol (2010) produced by Raizen, addressing key areas like improved yeast performance.
CEO of Raizen, Vasco Diaz, cited the timeliness of the agreement as Brazil begins importing ethanol to satisfy demand which is outstripping currently projected yields for the season. Diaz reaffirmed the commitment by CDXS and his company to helping solve the problem through technological innovation.
The agreement calls for commercialization rights to be retained by CDXS, with Raizen accessing preferential commercial terms and subsequent agreements slated to cover any successful developments that emerge under the current agreement. Interestingly, the agreement also includes the potential for collaborative efforts on other lucrative products like bio-based chemicals and similar sugar-derived offerings.
Today’s news is huge for CDXS and its shareholders as Brazil topped out in second place globally last year (2010) for both production (7B gallons) and consumption of ethanol.
President and CEO of CDXS, Alan Shaw, Ph.D., called the agreement a huge step for both Brazilian ethanol production and the two companies. This initial agreement, according to Shaw, will lay the foundation for the future while granting immediate improvement both to the performance and overall cost structure of first generation ethanol.
Raizen is turning out around 530M gallons of ethanol annually, making them Brazil’s third largest fuels company and with a 4,500 station network and 24 sugar mills, they boast an impressive installed capacity of some 900MW of energy from sugar cane. This is a perfect move for CDXS, opening up substantial territory in a thriving market that has real potential for long-term growth.
For more information on the agreement, the technology and/or on Codexis, Inc., please visit the Company’s website at: www.Codexis.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The agreement will see the Codexis CodeEvolver™ platform implemented in order to upgrade the existing process utilized by Raizen for manufacturing ethanol from sugar cane. Pilot production at Raizen’s Bonfim mill will look to accelerate the some 600M gallons of ethanol (2010) produced by Raizen, addressing key areas like improved yeast performance.
CEO of Raizen, Vasco Diaz, cited the timeliness of the agreement as Brazil begins importing ethanol to satisfy demand which is outstripping currently projected yields for the season. Diaz reaffirmed the commitment by CDXS and his company to helping solve the problem through technological innovation.
The agreement calls for commercialization rights to be retained by CDXS, with Raizen accessing preferential commercial terms and subsequent agreements slated to cover any successful developments that emerge under the current agreement. Interestingly, the agreement also includes the potential for collaborative efforts on other lucrative products like bio-based chemicals and similar sugar-derived offerings.
Today’s news is huge for CDXS and its shareholders as Brazil topped out in second place globally last year (2010) for both production (7B gallons) and consumption of ethanol.
President and CEO of CDXS, Alan Shaw, Ph.D., called the agreement a huge step for both Brazilian ethanol production and the two companies. This initial agreement, according to Shaw, will lay the foundation for the future while granting immediate improvement both to the performance and overall cost structure of first generation ethanol.
Raizen is turning out around 530M gallons of ethanol annually, making them Brazil’s third largest fuels company and with a 4,500 station network and 24 sugar mills, they boast an impressive installed capacity of some 900MW of energy from sugar cane. This is a perfect move for CDXS, opening up substantial territory in a thriving market that has real potential for long-term growth.
For more information on the agreement, the technology and/or on Codexis, Inc., please visit the Company’s website at: www.Codexis.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Scorpex, Inc. (SRPX) Taps Major Market Opportunity in Mexico
Mexico, like any country, has its share of internal challenges. But none of that seems to have dimmed the consensus that the country will play an expanding economic role in North America and the world over the next decade. A growing population gives Mexico a demographic profile that a number of industrialized countries would envy. Its economic fundamentals have generally improved over the last 20 years, in spite of the inevitable effects of the current global economic crisis, with industrial development and privatization continuing to expand.
The result of all this has been a growing need for improved waste handling throughout Mexico, and especially in the Baja Peninsula, a popular tourist and agricultural center with its own growing economy.
Scorpex has clearly recognized the possibilities, and is well along the way toward completing a long anticipated and much in demand full service waste disposal and recycling operation near Ensenada along the northwest coast of Baja, only about 25 miles south of Mexico’s border with California. It will be a state-of-the-art facility, able to process all manner of waste, including toxic and hazardous. Scorpex has financed and is set to install a sophisticated waste gasification and thermal oxidation system, and already has more customers lined up than it can handle. But this is just the beginning. The company’s long term plans call for additional facilities, strategically positioned throughout Mexico.
Taking advantage of Mexico’s expanding waste processing market is not a simple process. In addition to having a clear sense of the market, a major strength of Scorpex is its demonstrated ability to build and maintain a strong and positive working relationship with the Mexican government and local communities, which is necessary to obtain all of the required approvals and a discouragement to potential competitors.
For additional information on Scorpex, visit the company’s website at www.Scorpex.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The result of all this has been a growing need for improved waste handling throughout Mexico, and especially in the Baja Peninsula, a popular tourist and agricultural center with its own growing economy.
Scorpex has clearly recognized the possibilities, and is well along the way toward completing a long anticipated and much in demand full service waste disposal and recycling operation near Ensenada along the northwest coast of Baja, only about 25 miles south of Mexico’s border with California. It will be a state-of-the-art facility, able to process all manner of waste, including toxic and hazardous. Scorpex has financed and is set to install a sophisticated waste gasification and thermal oxidation system, and already has more customers lined up than it can handle. But this is just the beginning. The company’s long term plans call for additional facilities, strategically positioned throughout Mexico.
Taking advantage of Mexico’s expanding waste processing market is not a simple process. In addition to having a clear sense of the market, a major strength of Scorpex is its demonstrated ability to build and maintain a strong and positive working relationship with the Mexican government and local communities, which is necessary to obtain all of the required approvals and a discouragement to potential competitors.
For additional information on Scorpex, visit the company’s website at www.Scorpex.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Mines Management (MGN) Completes Key Component for Final Phase of Montanore Project
Mines Management Inc., engaged in the business of acquiring, exploring and developing mineral properties containing precious and base metals in Montana, today announced that a Supplemental Draft Environmental Impact Statement (SDEIS) has been completed by the U.S. Forest Service for the Montanore Project.
The SDEIS is a significant component of the Mines Management’s long-standing process with the Montanore Project.
“Completion of the SDEIS is a major step forward in the final phase of the permitting process,” Glenn M. Dobbs, president and CEO of Mines Management stated in the press release. “It signals a move toward completion of the process we began in 2005, since which time we have developed extensive documentation demonstrating the benign nature of this underground mining project, and the protections to the environment provided in the plan of operations.”
The company designed the mine to exceed current standards and regulations to ensure the protection of wildlife while maintaining purity and viability of water in the region, and reduce other perceived risks to the environment. Dobbs also noted how the project will generate employment opportunities.
“Since 1993, the project has undergone additional exhaustive studies, and it is clear the community in the area of the project would like to see the mine built. If developed, the Montanore Project would provide an estimated 350 direct long-term jobs in a community with approximately 20 percent unemployment, resulting in significant economic growth and an increase in the tax base,” Dobbs stated. “With the completion of the SDEIS, we are optimistic that the permitting process is nearing a conclusion, after which the project can move forward.”
Contingent upon obtaining a full permit for the Montanore Project, the company said it intends to complete the rehabilitation and construction of its 14,000 ft. evaluation adit, as well as complete an underground drilling program.
For more information visit www.minesmanagement.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The SDEIS is a significant component of the Mines Management’s long-standing process with the Montanore Project.
“Completion of the SDEIS is a major step forward in the final phase of the permitting process,” Glenn M. Dobbs, president and CEO of Mines Management stated in the press release. “It signals a move toward completion of the process we began in 2005, since which time we have developed extensive documentation demonstrating the benign nature of this underground mining project, and the protections to the environment provided in the plan of operations.”
The company designed the mine to exceed current standards and regulations to ensure the protection of wildlife while maintaining purity and viability of water in the region, and reduce other perceived risks to the environment. Dobbs also noted how the project will generate employment opportunities.
“Since 1993, the project has undergone additional exhaustive studies, and it is clear the community in the area of the project would like to see the mine built. If developed, the Montanore Project would provide an estimated 350 direct long-term jobs in a community with approximately 20 percent unemployment, resulting in significant economic growth and an increase in the tax base,” Dobbs stated. “With the completion of the SDEIS, we are optimistic that the permitting process is nearing a conclusion, after which the project can move forward.”
Contingent upon obtaining a full permit for the Montanore Project, the company said it intends to complete the rehabilitation and construction of its 14,000 ft. evaluation adit, as well as complete an underground drilling program.
For more information visit www.minesmanagement.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
ON Semiconductor Corp. (ONNN) Receives Home Electronic Product Design 2011 Award for their Energy Efficient, High Precision Mixed-Signal Microcontroller
ON Semiconductor, which wields an impressive manufacturing, design and supply chain infrastructure in energy efficient silicon devices from its corporate HQ in Phoenix, AZ, recently received the Electronic Product Design 2011 e-Legacy Award in Medical Advances for their Q32M210 Precision Mixed-Signal 32-bit Microcontroller.
Built on a rock-solid programmable ARM® Cortex™-M3 processor foundation, the Q32M210 delivers maximum code portability, coupled with a low-noise analog front-end that can be configured for whatever product developers need. When it comes to robust, continuous precision measurement in a portable sensing environment, the Q32M210 sets new standards for tight integration, performance and reliability.
Dual 16-bit ADCs deliver high-fidelity voltage reference and triple 10-bit DACs, meaning vastly lower noise than in competing, linear solutions. On-chip power supervision, redundant flash memory storage (error checking/correction circuitry), a variety of peripheral interfaces for external UIs via USB and many other key features make the Q32M210 salient.
The icing on the cake is the energy efficiency profile, bringing high performance at exceptional power efficiency rates; this design effectively results in an extremely flexible, scalable measurement engine that allows for a range of finely tuned price/performance ratios to be set by developers during deployment operations.
Senior Director, Consumer Health Products for ONNN, Michel De Mey, hailed the clear thumbs up from Electronic Product Design as a true honor, noting that it has always been the goal of the Company to be at the tip of the spear in “shaping the future of the medical electronics industry”. De Mey underscored the tremendous potential for burgeoning end-markets like blood glucose monitoring, wireless ECG, pulse oximeters and other portable sensing equipment, pointing to the Q32M210 as a potential silver bullet.
Indeed the device has wide-ranging applications, even in other, non-medical applications, like home-based displays for energy monitoring or even fitness monitoring devices. By fusing together a solution to the real-world concerns of device power consumption and battery life, with a powerful, high-precision measurement engine, ONNN has earned the recognition Electronic Product Design and developers as well.
For more information on the Q32M210 award and ON Semiconductor, please visit the Company’s website at: www.OnSemi.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Built on a rock-solid programmable ARM® Cortex™-M3 processor foundation, the Q32M210 delivers maximum code portability, coupled with a low-noise analog front-end that can be configured for whatever product developers need. When it comes to robust, continuous precision measurement in a portable sensing environment, the Q32M210 sets new standards for tight integration, performance and reliability.
Dual 16-bit ADCs deliver high-fidelity voltage reference and triple 10-bit DACs, meaning vastly lower noise than in competing, linear solutions. On-chip power supervision, redundant flash memory storage (error checking/correction circuitry), a variety of peripheral interfaces for external UIs via USB and many other key features make the Q32M210 salient.
The icing on the cake is the energy efficiency profile, bringing high performance at exceptional power efficiency rates; this design effectively results in an extremely flexible, scalable measurement engine that allows for a range of finely tuned price/performance ratios to be set by developers during deployment operations.
Senior Director, Consumer Health Products for ONNN, Michel De Mey, hailed the clear thumbs up from Electronic Product Design as a true honor, noting that it has always been the goal of the Company to be at the tip of the spear in “shaping the future of the medical electronics industry”. De Mey underscored the tremendous potential for burgeoning end-markets like blood glucose monitoring, wireless ECG, pulse oximeters and other portable sensing equipment, pointing to the Q32M210 as a potential silver bullet.
Indeed the device has wide-ranging applications, even in other, non-medical applications, like home-based displays for energy monitoring or even fitness monitoring devices. By fusing together a solution to the real-world concerns of device power consumption and battery life, with a powerful, high-precision measurement engine, ONNN has earned the recognition Electronic Product Design and developers as well.
For more information on the Q32M210 award and ON Semiconductor, please visit the Company’s website at: www.OnSemi.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Fuel Tech, Inc. (FTEK) Receives Multiple New Contracts both Foreign and Domestic for Air Pollution Control Projects Totaling $3 Million
Fuel Tech, a world leader in advanced engineering solutions for combustion and emissions control systems for utility and industrial applications, yesterday announced that it has signed several new contracts for air pollution control that total $3.0 million. These contracts were signed with both new and existing clients in the US and abroad.
Two orders were received from Chinese power plants for the ULTRA systems process that safely and cheaply convert urea to ammonia for use as a reagent in the reduction of nitrogen oxide (NOx) thus eliminating the danger associated with the transport, storage, and handling of aqueous ammonia or anhydrous. The largest order is from an existing client to retrofit two large coal units and the second order is for two medium sized coal operations. Equipment should be delivered in late 2011 for both clients.
The new Cross-State Air Pollution Rule, which becomes law in the United States at the start of 2012, drove a major domestic utility company to purchase Fuel Tech’s Selective Non-Catalytic Reduction (SNCR) systems to address NOx emissions at an unnamed power plant. Also, other domestic orders for Computational Fluid Dynamiz (CFD) modeling relate to this new rule and point to future sales.
“We continue to gain traction in the Chinese market, in particular with our proprietary ULTRA technology. China continues to be a very active market for all of our technologies as new regulations are now in place for broad reductions of NOx emissions. Additionally, we are pleased that these domestic utility customers have selected Fuel Tech to implement equipment solutions and evaluate short term strategies to achieve compliance in a dynamic regulatory environment that is calling for greater reductions in NOx emissions under the new Cross-State Air Pollution Rule. Fuel Tech’s SNCR technology can provide our customers with timely NOx reductions where boilers may operate across a wide load range, and these flexible systems are designed to complement additional Fuel Tech NOx reduction technologies, including combustion modifications, ASCR™ (Advanced Selective Catalytic Reduction) and conventional SCR,” said Douglas G. Bailey, Chairman, President and Chief Executive Officer, Fuel Tech in a press release.
For more information, please visit Fuel Tech’s web site at www.ftek.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Two orders were received from Chinese power plants for the ULTRA systems process that safely and cheaply convert urea to ammonia for use as a reagent in the reduction of nitrogen oxide (NOx) thus eliminating the danger associated with the transport, storage, and handling of aqueous ammonia or anhydrous. The largest order is from an existing client to retrofit two large coal units and the second order is for two medium sized coal operations. Equipment should be delivered in late 2011 for both clients.
The new Cross-State Air Pollution Rule, which becomes law in the United States at the start of 2012, drove a major domestic utility company to purchase Fuel Tech’s Selective Non-Catalytic Reduction (SNCR) systems to address NOx emissions at an unnamed power plant. Also, other domestic orders for Computational Fluid Dynamiz (CFD) modeling relate to this new rule and point to future sales.
“We continue to gain traction in the Chinese market, in particular with our proprietary ULTRA technology. China continues to be a very active market for all of our technologies as new regulations are now in place for broad reductions of NOx emissions. Additionally, we are pleased that these domestic utility customers have selected Fuel Tech to implement equipment solutions and evaluate short term strategies to achieve compliance in a dynamic regulatory environment that is calling for greater reductions in NOx emissions under the new Cross-State Air Pollution Rule. Fuel Tech’s SNCR technology can provide our customers with timely NOx reductions where boilers may operate across a wide load range, and these flexible systems are designed to complement additional Fuel Tech NOx reduction technologies, including combustion modifications, ASCR™ (Advanced Selective Catalytic Reduction) and conventional SCR,” said Douglas G. Bailey, Chairman, President and Chief Executive Officer, Fuel Tech in a press release.
For more information, please visit Fuel Tech’s web site at www.ftek.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Monday, September 26, 2011
IsoRay, Inc. (ISR) Radiation Technology used in World’s First Treatment of Metastasized Brain Cancer
Medical technology company IsoRay today announced that doctors at New York Presbyterian Hospital/ Weill Cornell Medical Center have performed the world’s first treatment of metastasized brain cancer using IsoRay’s Cesium-131 brachytherapy (internal radiation therapy) seeds, which previously received FDA clearance for the treatment of various cancers.
Treatment of metastasized cancers, which are cancers that spread from the site of the original tumor, is IsoRay’s latest application of pioneering brachytherapy treatment, representing milestone advancement in internal radiation therapy.
Doctors at the Medical Center implanted the seeds directly into a woman’s brain to treat a cancer that had originated in the breast.
Brain cancer treatment often involves removal of the brain tumor and weeks of recovery before external beam radiation treatment can begin. This time gap can increase the chance of tumor recurrence. New York Presbyterian Radiation Oncologist Dr. A. Gabriella Wernicke, M.D., M.Sc., said Cesium-131 is an important alternative because it gives doctors the opportunity to act immediately.
Cesium-131 offers several other benefits over current alternatives, including the advantage that it does not require weeks of follow-on treatment necessary with traditional external beam radiation, which involves numerous return trips to the hospital. IsoRay said Cesium-131 seeds offer rapid and aggressive delivery of radiation compared to other types of internal, low dose rate radiation and limit damage to healthy surrounding tissues and organs, directly impacting longevity and the potential of recurrence.
“The thought leaders at New York Presbyterian Hospital/Weill Cornell Medical Center were among the early adopters of Cesium-131 because they were quick to recognize the important advantages Cesium-131 offers patients. I strongly believe that adoption of Cesium-131 for the treatment of primary and metastasized cancers will continue growing at an increasing rate as the medical community becomes aware of the significant advantages it offers in treating cancer sites throughout the body,” IsoRay CEO Dwight Babcock stated.
Since the successful treatment of the first patient, doctors at New York Presbyterian/Weill Cornell Medical Center used IsoRay’s patented Cesium-131 brachytherapy seeds to treat more than 20 other patients with recurrent Glioblastomas, as well as metastasized brain cancer.
For more information visit www.isoray.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Treatment of metastasized cancers, which are cancers that spread from the site of the original tumor, is IsoRay’s latest application of pioneering brachytherapy treatment, representing milestone advancement in internal radiation therapy.
Doctors at the Medical Center implanted the seeds directly into a woman’s brain to treat a cancer that had originated in the breast.
Brain cancer treatment often involves removal of the brain tumor and weeks of recovery before external beam radiation treatment can begin. This time gap can increase the chance of tumor recurrence. New York Presbyterian Radiation Oncologist Dr. A. Gabriella Wernicke, M.D., M.Sc., said Cesium-131 is an important alternative because it gives doctors the opportunity to act immediately.
Cesium-131 offers several other benefits over current alternatives, including the advantage that it does not require weeks of follow-on treatment necessary with traditional external beam radiation, which involves numerous return trips to the hospital. IsoRay said Cesium-131 seeds offer rapid and aggressive delivery of radiation compared to other types of internal, low dose rate radiation and limit damage to healthy surrounding tissues and organs, directly impacting longevity and the potential of recurrence.
“The thought leaders at New York Presbyterian Hospital/Weill Cornell Medical Center were among the early adopters of Cesium-131 because they were quick to recognize the important advantages Cesium-131 offers patients. I strongly believe that adoption of Cesium-131 for the treatment of primary and metastasized cancers will continue growing at an increasing rate as the medical community becomes aware of the significant advantages it offers in treating cancer sites throughout the body,” IsoRay CEO Dwight Babcock stated.
Since the successful treatment of the first patient, doctors at New York Presbyterian/Weill Cornell Medical Center used IsoRay’s patented Cesium-131 brachytherapy seeds to treat more than 20 other patients with recurrent Glioblastomas, as well as metastasized brain cancer.
For more information visit www.isoray.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
American Superconductor (AMSC) Highlights Key Achievements supporting Global Reach
Global power technologies company American Superconductor Corp. recently issued an update on its recent performance and accomplishments in the wind power and power grid markets, including its achievement of nearly $100 million in new contracts since the start of the company’s fiscal year on April 1, 2011.
Since the beginning of April, the company has signed contracts with wind turbine manufacturers in China, India and Korea. It has also received orders for its grid interconnection and high voltage stability solutions in the U.S. and Europe, reflecting its global market reach.
“We are pleased to announce these key accomplishments across the Americas, Europe and Asia and our Wind and Grid solutions,” AMSC president and CEO Daniel McGahn stated in the press release. “Through our best-in-class wind turbine designs, superior electrical control systems, and highly efficient transmission and distribution products, AMSC solutions are serving as a catalyst for customer success and providing cleaner, smarter and more efficient energy for the world.”
In China, AMSC inked a multi-year deal to deliver wind turbine ECS to a subsidiary of state-owned Beijing JINGCHENG Machinery Electric Holding Co. Ltd, which AMSC plans to ship from late 2011 through 2014.
In India, the company signed a contract to deliver wind turbine ECS to Inox Wind Ltd., with shipments expected to begin in late 2011 and run through 2012.
AMCS also signed a contract in South Korea, in which the company will provide wind turbine core electrical components to Hyundai Heavy Industries (HHI) later this year.
AMSC’s Grid solutions allow for the developers of wind farm and solar power plant to integrate renewable power into the grid and allow electric utilities to optimize their transmission and distribution networks.
In this arena, AMSC signed a multi-million dollar contract to provide a D-VAR® system for Keys Energy Services, a public power utility in Florida.
The company also inked several new grid integration solution contracts in Europe, related to wind farms and solar power plants; in this instance, AMSC will integrate more than 150 MW of renewable energy into the grid.
In South Korea, AMSC made its first Amperium™ wire shipment to LS Cable & System under a multi-year supply agreement announced in October 2010.
For more information visit www.amsc.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Since the beginning of April, the company has signed contracts with wind turbine manufacturers in China, India and Korea. It has also received orders for its grid interconnection and high voltage stability solutions in the U.S. and Europe, reflecting its global market reach.
“We are pleased to announce these key accomplishments across the Americas, Europe and Asia and our Wind and Grid solutions,” AMSC president and CEO Daniel McGahn stated in the press release. “Through our best-in-class wind turbine designs, superior electrical control systems, and highly efficient transmission and distribution products, AMSC solutions are serving as a catalyst for customer success and providing cleaner, smarter and more efficient energy for the world.”
In China, AMSC inked a multi-year deal to deliver wind turbine ECS to a subsidiary of state-owned Beijing JINGCHENG Machinery Electric Holding Co. Ltd, which AMSC plans to ship from late 2011 through 2014.
In India, the company signed a contract to deliver wind turbine ECS to Inox Wind Ltd., with shipments expected to begin in late 2011 and run through 2012.
AMCS also signed a contract in South Korea, in which the company will provide wind turbine core electrical components to Hyundai Heavy Industries (HHI) later this year.
AMSC’s Grid solutions allow for the developers of wind farm and solar power plant to integrate renewable power into the grid and allow electric utilities to optimize their transmission and distribution networks.
In this arena, AMSC signed a multi-million dollar contract to provide a D-VAR® system for Keys Energy Services, a public power utility in Florida.
The company also inked several new grid integration solution contracts in Europe, related to wind farms and solar power plants; in this instance, AMSC will integrate more than 150 MW of renewable energy into the grid.
In South Korea, AMSC made its first Amperium™ wire shipment to LS Cable & System under a multi-year supply agreement announced in October 2010.
For more information visit www.amsc.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
VistaGen Therapeutics, Inc. (VSTA) Announces Significant Progression in its Pancreatic Cell and Regenerative Medicine Programs
VistaGen Therapeutics, Inc., a biotechnology company applying stem cell technology for drug rescue and cell therapy, just announced the publication of its original research demonstrating the use of pluripotent stem cells to generate insulin in mice. The studies are part of VistaGen’s Human Clinical Trials in a Test Tube(TM) platform which has proprietary applications in drug screening, cell therapy, and regenerative medicine in the areas of metabolic disease and diabetes.
The research, titled Pdx1 and Ngn3 Overexpression Enhances Pancreatic Differentiation of Mouse ES Cell-Derived Endoderm Population, originated from a collaboration between VistaGen and the laboratories of Dr. Gordon Keller at the University Health Network’s McEwen Centre for Regenerative Medicine in Toronto and Dr. Atsushi Kubo at Nara Medical University in Japan. It was published in the peer-reviewed journal, PLoS ONE 6(9): e24058, doi: 10.1371/journal.pone.0024058 on September 13, 2011.
Dr. Ralph Snodgrass, President and Chief Scientific Officer of VistaGen, stated, “In addition to presenting a powerful in vitro model system designed to screen for potential genes or drug candidates capable of inducing the production of insulin-secreting pancreatic beta-islet cells, these research results represent another important step towards our goal of developing superior biological systems for drug development. We are grateful for the scientific contributions of our international collaborators to the research reported in this publication, as well as the continuing technical progress we are making through our ongoing and active partnership with Dr. Gordon Keller and his laboratory in Toronto.”
VistaGen has a strong history of successfully advancing its internal commercially-focused research and development programs through collaborations that strategically combine the complementary capabilities of its industry leading scientists with academic leaders in the field of stem cell research. The published results are the consummation of a close and productive international collaboration initiated and led by VistaGen scientists.
The stem cell-derived pancreatic cells developed by the international research team demonstrated the ability to produce and correctly process insulin and secrete C-peptide, characteristics of mature beta-islet cells. In addition, these studies suggest a potential purification or enrichment strategy for beta-islet cell production, facilitating a strategy for the production of large numbers of beta-islet cells for multiple applications. They also point to additional areas for future development as well as provide a strong foundation that supports VistaGen’s efforts to produce fully functional human beta-islet cells for drug discovery and clinical applications.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The research, titled Pdx1 and Ngn3 Overexpression Enhances Pancreatic Differentiation of Mouse ES Cell-Derived Endoderm Population, originated from a collaboration between VistaGen and the laboratories of Dr. Gordon Keller at the University Health Network’s McEwen Centre for Regenerative Medicine in Toronto and Dr. Atsushi Kubo at Nara Medical University in Japan. It was published in the peer-reviewed journal, PLoS ONE 6(9): e24058, doi: 10.1371/journal.pone.0024058 on September 13, 2011.
Dr. Ralph Snodgrass, President and Chief Scientific Officer of VistaGen, stated, “In addition to presenting a powerful in vitro model system designed to screen for potential genes or drug candidates capable of inducing the production of insulin-secreting pancreatic beta-islet cells, these research results represent another important step towards our goal of developing superior biological systems for drug development. We are grateful for the scientific contributions of our international collaborators to the research reported in this publication, as well as the continuing technical progress we are making through our ongoing and active partnership with Dr. Gordon Keller and his laboratory in Toronto.”
VistaGen has a strong history of successfully advancing its internal commercially-focused research and development programs through collaborations that strategically combine the complementary capabilities of its industry leading scientists with academic leaders in the field of stem cell research. The published results are the consummation of a close and productive international collaboration initiated and led by VistaGen scientists.
The stem cell-derived pancreatic cells developed by the international research team demonstrated the ability to produce and correctly process insulin and secrete C-peptide, characteristics of mature beta-islet cells. In addition, these studies suggest a potential purification or enrichment strategy for beta-islet cell production, facilitating a strategy for the production of large numbers of beta-islet cells for multiple applications. They also point to additional areas for future development as well as provide a strong foundation that supports VistaGen’s efforts to produce fully functional human beta-islet cells for drug discovery and clinical applications.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Multimedia Games Holding Company, Inc. (MGAM) Granted Licenses by Nevada Gaming Commission for Slot Machines in Largest Gaming Market
Multimedia Games Inc., a subsidiary of Multimedia Games Holding Company Inc., announced that the Nevada Gaming Commission has approved manufacturer’s and distributor’s licenses for the company, moving them one step closer to selling and/or leasing slot machines in the State of Nevada. Multimedia is on track to have its first sales and placement of slot machines in Nevada around October 2012. The last hurdle is that the Nevada State Gaming Control Board’s Technology Division needs to review and approve the MForce (TM) platform used by Multimedia Games.
Nevada has about 187,000 slot machines in facilities around the state making it the largest gaming market in North America. There is one operating slot machine in Las Vegas for every 8 residents.
“We appreciate the efforts of both the Nevada Gaming Commission and the Nevada State Gaming Control Board for their consideration and approval of our license application. Since the beginning of fiscal 2010, we have secured over 67 new licenses, and we are particularly pleased to now be licensed in Nevada the largest gaming market in North America,” said Patrick Ramsey, president and CEO, Multimedia Games in a press release on Friday from their Austin headquarters. “We look forward to offering games on our new operating platform to customers in Nevada following the required evaluation and approval process. We believe our games will provide slot players with new, unique entertainment experiences while delivering an attractive return on investment to casino operators.”
Since 1991, Multimedia Games has developed electronic gambling devices for American Indian gaming markets, commercial casinos, charity and international bingo markets. Multimedia also supplies the technology for the video lottery terminals installed at New York State Raceways. Last month the company posted a $2.7 million profit on $33.3 million in revenue for the third quarter ending June 30. In May the company reported a $1.2 million second-quarter profit versus a $5.6 million loss during the same period last year.
For more information on Multimedia Games, please visit www.multimediagames.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Nevada has about 187,000 slot machines in facilities around the state making it the largest gaming market in North America. There is one operating slot machine in Las Vegas for every 8 residents.
“We appreciate the efforts of both the Nevada Gaming Commission and the Nevada State Gaming Control Board for their consideration and approval of our license application. Since the beginning of fiscal 2010, we have secured over 67 new licenses, and we are particularly pleased to now be licensed in Nevada the largest gaming market in North America,” said Patrick Ramsey, president and CEO, Multimedia Games in a press release on Friday from their Austin headquarters. “We look forward to offering games on our new operating platform to customers in Nevada following the required evaluation and approval process. We believe our games will provide slot players with new, unique entertainment experiences while delivering an attractive return on investment to casino operators.”
Since 1991, Multimedia Games has developed electronic gambling devices for American Indian gaming markets, commercial casinos, charity and international bingo markets. Multimedia also supplies the technology for the video lottery terminals installed at New York State Raceways. Last month the company posted a $2.7 million profit on $33.3 million in revenue for the third quarter ending June 30. In May the company reported a $1.2 million second-quarter profit versus a $5.6 million loss during the same period last year.
For more information on Multimedia Games, please visit www.multimediagames.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Thursday, September 22, 2011
VistaGen Therapeutics Inc. (VSTA) Leadership Eyes Huge Financial Impact of Stem Cell Developments
When VistaGen Therapeutics announced the appointment of Shawn K. Singh as its CEO, Mr. Singh’s reputation and familiarity with the company had already been established. As Managing Principal of Cato BioVentures, VistaGen’s biggest institutional stockholder, and part-time President of VistaGen, he already knew VistaGen, its goals and its potential.
VistaGen, a South San Francisco based biotech company, is using pluripotent stem cell technologies to develop a new generation of cost-effective, clinically-relevant drug screening systems, offering the possibility of identifying potential toxicity issues early in the drug development process, well before massive amounts of money are lost in developing a drug that is later determined to be toxic to the human heart. It also means that promising new drugs currently shelved because of heart safety concerns can now be economically re-investigated for safer variants, potentially resulting in highly profitable new therapies that would otherwise never make it to market.
The financial potential of VistaGen’s stem cell technology was not lost on Singh, who began his career as a corporate finance attorney in Silicon Valley, and went on to serve in key executive positions with other successful biopharmaceutical and medical device companies, in addition to his tenure as a venture capitalist focused on the biotechnology sector. The possibility of using leading-edge stem cell biology to leverage and potentially recover billions of dollars previously invested by the pharmaceutical industry and thought to be lost in the development of now shelved drugs is too big for the industry to ignore.
VistaGen’s founder, H. Ralph Snodgrass, a Ph.D., is a recognized expert in pioneering stem cell research. Dr. Snodrass has extensive research experience as a professor at the Lineberger Comprehensive Cancer Center in North Carolina, and as a member of the Institute for Immunology in Switzerland. He is a past board member of the Emerging Company Section of the Biotechnology Industry Organization, and has many years of experience in the use of stem cells as biological tools for drug discovery and development. Dr. Snodgrass now serves as VistaGen’s President and Chief Scientific Officer, driving the company’s technical progress.
For additional information, visit the company’s website at www.VistaGen.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
VistaGen, a South San Francisco based biotech company, is using pluripotent stem cell technologies to develop a new generation of cost-effective, clinically-relevant drug screening systems, offering the possibility of identifying potential toxicity issues early in the drug development process, well before massive amounts of money are lost in developing a drug that is later determined to be toxic to the human heart. It also means that promising new drugs currently shelved because of heart safety concerns can now be economically re-investigated for safer variants, potentially resulting in highly profitable new therapies that would otherwise never make it to market.
The financial potential of VistaGen’s stem cell technology was not lost on Singh, who began his career as a corporate finance attorney in Silicon Valley, and went on to serve in key executive positions with other successful biopharmaceutical and medical device companies, in addition to his tenure as a venture capitalist focused on the biotechnology sector. The possibility of using leading-edge stem cell biology to leverage and potentially recover billions of dollars previously invested by the pharmaceutical industry and thought to be lost in the development of now shelved drugs is too big for the industry to ignore.
VistaGen’s founder, H. Ralph Snodgrass, a Ph.D., is a recognized expert in pioneering stem cell research. Dr. Snodrass has extensive research experience as a professor at the Lineberger Comprehensive Cancer Center in North Carolina, and as a member of the Institute for Immunology in Switzerland. He is a past board member of the Emerging Company Section of the Biotechnology Industry Organization, and has many years of experience in the use of stem cells as biological tools for drug discovery and development. Dr. Snodgrass now serves as VistaGen’s President and Chief Scientific Officer, driving the company’s technical progress.
For additional information, visit the company’s website at www.VistaGen.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
SORL Auto Parts, Inc. (SORL) Creates European Subsidiary to Win More Security Related Auto Parts Contracts with Truck, Bus and Trailer Manufacturers across Europe
SORL Auto Parts, Inc., a leading Chinese supplier of brake and control systems to the global commercial vehicle industry, announced today the creation of a new subsidiary, SORL Europe, to win more contracts and service customers in Europe, Middle East and Africa. SORL Europe will market its quality certified products to truck, trailer and bus manufacturers and look to increase its aftermarket distribution network. The new subsidiary will be located in Brussels, Belgium and will be headed by Jean Francois Barth, Vice President of International Markets and Managing Director SORL.
SORL Auto Parts principally manufactures and distributes automotive brake systems and other key security related auto parts directly to automotive original equipment manufacturers. The Company’s products primarily are used in commercial vehicles like trucks and buses. It is China’s largest commercial airbrake system manufacturer with over half of its customers comprised of China’s major vehicle manufacturers. The European brake market is posed to be an important vehicle for growth with 10 percent growth projected this year for aftermarket products.
“We believe there is a significant opportunity for SORL to expand its presence in these growing markets. The European truck market is particularly attractive as heavy-duty truck registrations increased over 50% in the first half of 2011 and the aftermarket consists of a large number of trucks between 4 and 9 years of service requiring replacement parts. Our product development strategy is focused on providing high-value solutions that increase driver safety. SORL is the best value brand for these markets providing the high-quality products and services our customers expect,” said Jean Francois Barth, Vice President of International Markets and Managing Director.
“SORL Europe is another step in our global expansion. SORL now has dedicated regional operations to enhance our penetration of these important markets. A more local presence will enable us to become more integrated with our customers so we can better anticipate their future requirements. We continue to design and manufacture our products to meet global standards so we can more quickly access and service foreign markets,” added Xiaoping Zhang, Chairman of the Board of Directors and Chief Executive Officer.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
SORL Auto Parts principally manufactures and distributes automotive brake systems and other key security related auto parts directly to automotive original equipment manufacturers. The Company’s products primarily are used in commercial vehicles like trucks and buses. It is China’s largest commercial airbrake system manufacturer with over half of its customers comprised of China’s major vehicle manufacturers. The European brake market is posed to be an important vehicle for growth with 10 percent growth projected this year for aftermarket products.
“We believe there is a significant opportunity for SORL to expand its presence in these growing markets. The European truck market is particularly attractive as heavy-duty truck registrations increased over 50% in the first half of 2011 and the aftermarket consists of a large number of trucks between 4 and 9 years of service requiring replacement parts. Our product development strategy is focused on providing high-value solutions that increase driver safety. SORL is the best value brand for these markets providing the high-quality products and services our customers expect,” said Jean Francois Barth, Vice President of International Markets and Managing Director.
“SORL Europe is another step in our global expansion. SORL now has dedicated regional operations to enhance our penetration of these important markets. A more local presence will enable us to become more integrated with our customers so we can better anticipate their future requirements. We continue to design and manufacture our products to meet global standards so we can more quickly access and service foreign markets,” added Xiaoping Zhang, Chairman of the Board of Directors and Chief Executive Officer.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
BioLineRx Ltd. (BLRX) to Retain KCSA Strategic Communications
Located in Jerusalem, BioLineRx is a publicly-traded company focused on building a portfolio of products for unmet medical needs or with advantages over currently available therapies. Today, BioLineRx took a major step towards prominence with the announcement they have retained KCSA Strategic Communications to direct their U.S. investor relations program.
KCSA is a leading New York-based communications firm that intends to deploy a comprehensive investor relations program with the goal of expanding the influence BioLineRx has within the United States.
Todd Fromer, whom is a Managing Partner of KCSA will lead the KCSA team and provide strategic counsel on financial communication matters. In reference to KCSA being retained by BioLine Rx, Fromer stated, “Since listing its ADR’s on the NASDAQ in July, BioLineRx has had little exposure to the U.S. investment community. As such, we believe there is a tremendous opportunity for us to broaden awareness among investors and highlight the opportunity BioLineRx and its products provide. As part of our program, we will work with the BioLineRx management team to effectively and regularly communicate with its U.S. investor base.”
BioLine Rx CEO Dr. Kinneret Savitsky commented, “I am excited to begin working with KCSA in order to create greater awareness of BioLineRx in the U.S. investment community. We have several exciting products in our pipeline that are in advanced stage clinical trials, providing us with significant short-term and long-term opportunities to grow our business. With KCSA’s proactive communications program, we hope to highlight the ongoing development of these products to our shareholders and potential value of these products upon receiving regulatory market clearance.”
Currently, BioLineRx is trading in the $3.49 range. To learn more about the company as a whole, visit their website at: www.biolinerx.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
KCSA is a leading New York-based communications firm that intends to deploy a comprehensive investor relations program with the goal of expanding the influence BioLineRx has within the United States.
Todd Fromer, whom is a Managing Partner of KCSA will lead the KCSA team and provide strategic counsel on financial communication matters. In reference to KCSA being retained by BioLine Rx, Fromer stated, “Since listing its ADR’s on the NASDAQ in July, BioLineRx has had little exposure to the U.S. investment community. As such, we believe there is a tremendous opportunity for us to broaden awareness among investors and highlight the opportunity BioLineRx and its products provide. As part of our program, we will work with the BioLineRx management team to effectively and regularly communicate with its U.S. investor base.”
BioLine Rx CEO Dr. Kinneret Savitsky commented, “I am excited to begin working with KCSA in order to create greater awareness of BioLineRx in the U.S. investment community. We have several exciting products in our pipeline that are in advanced stage clinical trials, providing us with significant short-term and long-term opportunities to grow our business. With KCSA’s proactive communications program, we hope to highlight the ongoing development of these products to our shareholders and potential value of these products upon receiving regulatory market clearance.”
Currently, BioLineRx is trading in the $3.49 range. To learn more about the company as a whole, visit their website at: www.biolinerx.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Apple, Inc. (AAPL) Remains Silent on iPod Lineup
The iPod saved Apple and revolutionized the music industry, while making investors happy as shares have surged a split-adjusted 4,562% since the music player made its debut on Oct. 23, 2001. However, its glory days may be over. Although more than 45 million iPods have been sold over the last four quarters alone, the 10th anniversary is approaching and there are signs that Apple is shifting more of its focus elsewhere.
The number of iPods that continue to sell are astounding, but sales are in decline. Unit sales are down 12.5% year-over-year and revenues have fallen 6.2%. Notably, Apple has been unusually quiet about their highly successful product line this year. We’re nearing the end of September and still there has not been a word from the company.
Yesterday reports emerged of an Apple event scheduled for October 4, but that the main focus would be on the iPhone, not the iPod lineup. Apple is not likely to build an event around a product that’s in retreat, even if it’s historically the most successful. The silence surrounding the iPod, combined with the fact that Apple didn’t unveil a new version of the iPhone at its developers’ conference in June, has added to the feeling that Apple will use whatever event is coming up to make the iPhone the star of its next show.
“This is Steve Jobs’s genius,” said Silicon Valley futurist thinker and Stanford University instructor Paul Saffo. “The guy destroys the industries he creates to create something new. Who else but Jobs would invent the whole music model with the stand-alone player, and then destroy the market for a stand-alone player by coming out with a phone and a pad?”
Like other industry changers, such as the personal computer and television, the iPod isn’t going away. Don’t forget there is an iPod application in every Apple iPhone and iPad. But even though the iPod will remain on Apple’s roster, it is obvious that after 10 years, its days in the starting lineup as a standalone player are done.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The number of iPods that continue to sell are astounding, but sales are in decline. Unit sales are down 12.5% year-over-year and revenues have fallen 6.2%. Notably, Apple has been unusually quiet about their highly successful product line this year. We’re nearing the end of September and still there has not been a word from the company.
Yesterday reports emerged of an Apple event scheduled for October 4, but that the main focus would be on the iPhone, not the iPod lineup. Apple is not likely to build an event around a product that’s in retreat, even if it’s historically the most successful. The silence surrounding the iPod, combined with the fact that Apple didn’t unveil a new version of the iPhone at its developers’ conference in June, has added to the feeling that Apple will use whatever event is coming up to make the iPhone the star of its next show.
“This is Steve Jobs’s genius,” said Silicon Valley futurist thinker and Stanford University instructor Paul Saffo. “The guy destroys the industries he creates to create something new. Who else but Jobs would invent the whole music model with the stand-alone player, and then destroy the market for a stand-alone player by coming out with a phone and a pad?”
Like other industry changers, such as the personal computer and television, the iPod isn’t going away. Don’t forget there is an iPod application in every Apple iPhone and iPad. But even though the iPod will remain on Apple’s roster, it is obvious that after 10 years, its days in the starting lineup as a standalone player are done.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Wednesday, September 21, 2011
Pearl Stream Implements QAD, Inc. (QADA) Enterprise Application to Support Boost in Plant Production
QAD Inc., a leading provider of enterprise software and services for global manufacturing companies, today announced that German-Korean-owned Pearl Stream, an electronic components manufacturer, has implemented QAD Enterprise Applications as part of the recent roll-out of its new plant in Poland.
Founded earlier this year, Pearl Stream’s plant began production in April, manufacturing more than 10,000 electronics components per day, for use in televisions, home appliances and the automotive market.
Pearl Stream began implementing QAD Enterprise Applications to support its aggressive production targets as part of its two-phased deployment strategy. The company said it chose QAD’s system for its scalability, rapid deployment capabilities and strong manufacturing focus.
“We had only four months to build a factory and start production. Selecting the right ERP provider was critical to minimizing our risk and maximizing our workflow, quickly,” Krzysztof Jarzyna, plant manager at Pearl Stream stated in the press release. “QAD Enterprise Applications meets our expectations perfectly. It is a transparent and easy-to-use system. We are convinced it will contribute to the success and further development of our company.”
The first phase of Pearl Stream’s two-phased deployment strategy utilized QAD modules as a means to support its business and management processes, as well as for purchasing, finance, inventory management and distribution.
Phase two of the strategy was completed in mid-July 2011 with the deployment of QAD Manufacturing. Pearl Stream says it is now properly positioned to increase production.
For more information visit www.qad.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Founded earlier this year, Pearl Stream’s plant began production in April, manufacturing more than 10,000 electronics components per day, for use in televisions, home appliances and the automotive market.
Pearl Stream began implementing QAD Enterprise Applications to support its aggressive production targets as part of its two-phased deployment strategy. The company said it chose QAD’s system for its scalability, rapid deployment capabilities and strong manufacturing focus.
“We had only four months to build a factory and start production. Selecting the right ERP provider was critical to minimizing our risk and maximizing our workflow, quickly,” Krzysztof Jarzyna, plant manager at Pearl Stream stated in the press release. “QAD Enterprise Applications meets our expectations perfectly. It is a transparent and easy-to-use system. We are convinced it will contribute to the success and further development of our company.”
The first phase of Pearl Stream’s two-phased deployment strategy utilized QAD modules as a means to support its business and management processes, as well as for purchasing, finance, inventory management and distribution.
Phase two of the strategy was completed in mid-July 2011 with the deployment of QAD Manufacturing. Pearl Stream says it is now properly positioned to increase production.
For more information visit www.qad.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Gentium (GENT) Posts Q2, HY 2011 Financial Results
Gentium S.p.A., an Italy-based biopharmaceutical company, yesterday reported financial results for the first half of 2011 and the quarter ended June 30, 2011. The company’s financial statements are prepared using the Euro as its functional currency as of June 30, 2011: EUR 1.00 = $1.44.
For the second quarter ended June 30, 2011, the company reported total revenues of EUR 6.72 million compared with EUR 7.55 million for the same period in 2010.
Operating costs and expenses for the second quarter 2011 were EUR 5.52 million compared with EUR 5.37 million reported for the second quarter of the year prior.
Gentium reported operating income of EUR 1.20 million for the second quarter of 2011 compared with EUR 2.17 million for the comparable quarter of last year.
Net income for the second quarter was EUR 0.97 million, or basic and diluted net income per share of EUR 0.07 and EUR 0.06, respectively, compared with EUR 2.35 million in the second quarter of 2010.
As of June 30, 2011, Gentium had cash and cash equivalents of EUR 9.83 million compared to EUR 8.74 million at December 31, 2010.
For the first half of 2011, Gentium reported total revenues of EUR 12.77 million compared to EUR 12.53 million in the first half of 2010.
Operating costs and expenses for the first six months of 2011 were EUR 9.69 million compared to EUR 10.47 million reported for the comparable period of 2010. The company noted that operating costs and expenses for the prior-year period include a one-time restructuring charge of EUR 0.95 million.
Operating income for the first half of 2011 was EUR 3.08 million compared to EUR 2.06 million reported in the first half of 2010.
Gentium reported net income for the period at EUR 2.67 million, or basic and diluted net income per share of EUR 0.17 and EUR 0.18 per share, respectively, compared to EUR 2.32 million, or EUR 0.15.
“We are pleased to report that Defibrotide product sales increased 25% compared with the prior-year period,” Salvatore Calabrese, senior vice president and CFO of Gentium stated in the press release. “Additionally, we have continued to be cash flow positive and profitable during the first half of 2011, and have decreased our long-term debt while investing in the establishment of our European sales infrastructure. We confirm our previously reported projection that Defibrotide product sales for 2011 are expected to increase 25%-30% over 2010, but due in large part to lower API revenues, we are revising our 2011 product sales forecast to be in the range of EUR 21-23 million instead of EUR 23–25 million as originally projected.”
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
For the second quarter ended June 30, 2011, the company reported total revenues of EUR 6.72 million compared with EUR 7.55 million for the same period in 2010.
Operating costs and expenses for the second quarter 2011 were EUR 5.52 million compared with EUR 5.37 million reported for the second quarter of the year prior.
Gentium reported operating income of EUR 1.20 million for the second quarter of 2011 compared with EUR 2.17 million for the comparable quarter of last year.
Net income for the second quarter was EUR 0.97 million, or basic and diluted net income per share of EUR 0.07 and EUR 0.06, respectively, compared with EUR 2.35 million in the second quarter of 2010.
As of June 30, 2011, Gentium had cash and cash equivalents of EUR 9.83 million compared to EUR 8.74 million at December 31, 2010.
For the first half of 2011, Gentium reported total revenues of EUR 12.77 million compared to EUR 12.53 million in the first half of 2010.
Operating costs and expenses for the first six months of 2011 were EUR 9.69 million compared to EUR 10.47 million reported for the comparable period of 2010. The company noted that operating costs and expenses for the prior-year period include a one-time restructuring charge of EUR 0.95 million.
Operating income for the first half of 2011 was EUR 3.08 million compared to EUR 2.06 million reported in the first half of 2010.
Gentium reported net income for the period at EUR 2.67 million, or basic and diluted net income per share of EUR 0.17 and EUR 0.18 per share, respectively, compared to EUR 2.32 million, or EUR 0.15.
“We are pleased to report that Defibrotide product sales increased 25% compared with the prior-year period,” Salvatore Calabrese, senior vice president and CFO of Gentium stated in the press release. “Additionally, we have continued to be cash flow positive and profitable during the first half of 2011, and have decreased our long-term debt while investing in the establishment of our European sales infrastructure. We confirm our previously reported projection that Defibrotide product sales for 2011 are expected to increase 25%-30% over 2010, but due in large part to lower API revenues, we are revising our 2011 product sales forecast to be in the range of EUR 21-23 million instead of EUR 23–25 million as originally projected.”
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
D. Medical Industries Ltd. (DMED) Announces Issuance of U.S. Patent No. 8,021,334 for Insulin Administration
D. Medical Industries Ltd., a medical device company focused on the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery, announced earlier today that it has been granted U.S. Patent No. 8,021,334, entitled “Drug Delivery Device and Method.”
This patent protects innovative valve technology that allows safe and reliable administration of a desired amount of insulin. In addition to other features, the technology is able to detect malfunctions that could lead to over or under administration. According to the press release, it’s an essential part of D. Medical’s proprietary Intellispring™ and Total Line Control™ systems, which are at the heart of its “Spring™ Zone” and “Spring™ Hybrid” insulin pumps.
Hezkiah Tsoory, D. Medical’s Chief Operating Officer, stated, “As we continue to work toward the commercialization of our Spring pump technology, it is important that the many innovations that define these products are well protected. This U.S. patent issuance serves to strengthen D. Medical’s already formidable intellectual property estate.”
D. Medical’s spring-based delivery mechanism is believed to be a cost-effective alternative to the motor and gear train mechanisms that drive competitive insulin pumps and also enables certain advantageous functions and design features. The company has developed an infusion set for insulin pumps and is focusing its research and development efforts on the development of next generation insulin pumps and a device that will combine a continuous glucose monitoring system and an insulin pump on the same patch.
For more information on D. Medical, please visit www.dmedicalindustries.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
This patent protects innovative valve technology that allows safe and reliable administration of a desired amount of insulin. In addition to other features, the technology is able to detect malfunctions that could lead to over or under administration. According to the press release, it’s an essential part of D. Medical’s proprietary Intellispring™ and Total Line Control™ systems, which are at the heart of its “Spring™ Zone” and “Spring™ Hybrid” insulin pumps.
Hezkiah Tsoory, D. Medical’s Chief Operating Officer, stated, “As we continue to work toward the commercialization of our Spring pump technology, it is important that the many innovations that define these products are well protected. This U.S. patent issuance serves to strengthen D. Medical’s already formidable intellectual property estate.”
D. Medical’s spring-based delivery mechanism is believed to be a cost-effective alternative to the motor and gear train mechanisms that drive competitive insulin pumps and also enables certain advantageous functions and design features. The company has developed an infusion set for insulin pumps and is focusing its research and development efforts on the development of next generation insulin pumps and a device that will combine a continuous glucose monitoring system and an insulin pump on the same patch.
For more information on D. Medical, please visit www.dmedicalindustries.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Tuesday, September 20, 2011
Energy Conversion Devices, Inc. (ENER) Products Used to Power One of the Largest Residential Solar Installations in the World
United Solar, a wholly owned subsidiary of Energy Conversion Devices, Inc. and leading global manufacturer of UNI-SOLAR(R) light-weight, flexible thin-film solar modules, announced before the opening bell today that its UNI-SOLAR brand photovoltaics have been used for one of the largest known residential solar installations in the world. Investors cheered this news as reflected by the 11.11% gain in share price and 1.1+ million volume.
Installed in Chatsworth, California at the residence of Mr. Carl Harberger, a well-regarded sustainable building designer, the solar panels will power lighting, electronics and heating and air conditioning systems. United Solar provided 259 UNI-SOLAR brand flexible, lightweight photovoltaic modules for the 24 kilowatt (kW) solar installation. California-based solar installation company ADR Solar Solutions, Inc. completed the project.
“ADR Solar Solutions, Inc. have designed and installed commercial and residential solar systems for the last seventeen years. We are thrilled to have added to our achievements the UNI-SOLAR installation in Chatsworth, Ca, making it one of the world’s largest residential installations,” stated Ms. Nancy Palmer, ADR’s Manager of Sales and Marketing. “UNI-SOLAR was the only application considered for this installation and is not only working as anticipated, but is a beautiful addition to the design of this state of the art home. ADR Solar Solutions, Inc. will use UNI-SOLAR on many upcoming projects with confidence and look forward to a rock solid relationship.”
According to today’s press release, Mr. Harberger chose UNI-SOLAR panels because of the many unique features of the product. Flexibility was noted specifically as it allowed a perfect fit on the curved rooftop surface. Mr. Harberger took advantage of the rebates offered by the Los Angeles Department of Water & Power as well as U.S. federal tax credits.
“United Solar is proud to be chosen for this opportunity, providing enough solar energy to power Mr. Harberger’s nearly 6,000 square foot home. This is a perfect example of how UNI-SOLAR lightweight solar laminates can be integrated directly into a residence for a cost-saving and renewable energy solution,” said Steve Szamocki, Senior Vice President of Sales-Americas of United Solar.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Installed in Chatsworth, California at the residence of Mr. Carl Harberger, a well-regarded sustainable building designer, the solar panels will power lighting, electronics and heating and air conditioning systems. United Solar provided 259 UNI-SOLAR brand flexible, lightweight photovoltaic modules for the 24 kilowatt (kW) solar installation. California-based solar installation company ADR Solar Solutions, Inc. completed the project.
“ADR Solar Solutions, Inc. have designed and installed commercial and residential solar systems for the last seventeen years. We are thrilled to have added to our achievements the UNI-SOLAR installation in Chatsworth, Ca, making it one of the world’s largest residential installations,” stated Ms. Nancy Palmer, ADR’s Manager of Sales and Marketing. “UNI-SOLAR was the only application considered for this installation and is not only working as anticipated, but is a beautiful addition to the design of this state of the art home. ADR Solar Solutions, Inc. will use UNI-SOLAR on many upcoming projects with confidence and look forward to a rock solid relationship.”
According to today’s press release, Mr. Harberger chose UNI-SOLAR panels because of the many unique features of the product. Flexibility was noted specifically as it allowed a perfect fit on the curved rooftop surface. Mr. Harberger took advantage of the rebates offered by the Los Angeles Department of Water & Power as well as U.S. federal tax credits.
“United Solar is proud to be chosen for this opportunity, providing enough solar energy to power Mr. Harberger’s nearly 6,000 square foot home. This is a perfect example of how UNI-SOLAR lightweight solar laminates can be integrated directly into a residence for a cost-saving and renewable energy solution,” said Steve Szamocki, Senior Vice President of Sales-Americas of United Solar.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
ShoreTel (SHOR) Partners with Tech Data Canada to Extend Market Reach, Meet Demand
ShoreTel (SHOR) Partners with Tech Data Canada to Extend Market Reach, Meet Demand
ShoreTel, a leading provider of IP phone systems, announced it has inked a new distribution agreement with Tech Data Canada, the Canadian subsidiary of Tech Data Corporation.
Tech Data Canada specializes in IP telephony, wireless networking and VoIP technologies, and has established a partner base of more than 5,000 technology resellers and solution providers. By partnering with Tech Data Canada, ShoreTel can offer resellers the ability to operate in local currencies and time zones with local inventory, ShoreTel products, and multi-vendor solutions.
The agreement also increases the availability of ShoreTel business communications solutions throughout Canada.
“Demand is high for an affordable, scalable business communications solution that is easy to deploy and will support an increasingly mobile workforce. We’re thrilled to work with Tech Data Canada to deliver ShoreTel’s brilliantly simple line of UC products throughout the Canadian market, and we are confident that the relationship will empower our partners and customers to find the ShoreTel solution best suited to their unique communications needs and resources,” George Pappas, country manager, Canada, ShoreTel, stated in the press release.
The partnership supports ShoreTel’s recently announced global two-tier channel distribution strategy, and Brian Gendron, general manager, Black Box Canada, said the partnership delivers an effective business opportunity for Black Box, as well as ShoreTel and Tech Data Canada.
“We’re pleased with the recent announcement from ShoreTel to enter into two-tier distribution for their industry leading Unified Communications and Mobility Solutions. This creates a highly efficient route to market for Black Box Network Services and our ShoreTel customers through Tech Data’s best in class logistics coupled with industry-leading e-business and IT tools,” Gendron stated in the press release. “We believe Tech Data’s superior capabilities and their attention to detail will help Black Box Network Services continue to meet and exceed the expectations of our enterprise customers. Black Box Network Services Canada is happy to be partnered with ShoreTel and Tech Data, both strong partners to help delight our customers and grow our Canadian business.”
For more information visit www.shoretel.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
ShoreTel, a leading provider of IP phone systems, announced it has inked a new distribution agreement with Tech Data Canada, the Canadian subsidiary of Tech Data Corporation.
Tech Data Canada specializes in IP telephony, wireless networking and VoIP technologies, and has established a partner base of more than 5,000 technology resellers and solution providers. By partnering with Tech Data Canada, ShoreTel can offer resellers the ability to operate in local currencies and time zones with local inventory, ShoreTel products, and multi-vendor solutions.
The agreement also increases the availability of ShoreTel business communications solutions throughout Canada.
“Demand is high for an affordable, scalable business communications solution that is easy to deploy and will support an increasingly mobile workforce. We’re thrilled to work with Tech Data Canada to deliver ShoreTel’s brilliantly simple line of UC products throughout the Canadian market, and we are confident that the relationship will empower our partners and customers to find the ShoreTel solution best suited to their unique communications needs and resources,” George Pappas, country manager, Canada, ShoreTel, stated in the press release.
The partnership supports ShoreTel’s recently announced global two-tier channel distribution strategy, and Brian Gendron, general manager, Black Box Canada, said the partnership delivers an effective business opportunity for Black Box, as well as ShoreTel and Tech Data Canada.
“We’re pleased with the recent announcement from ShoreTel to enter into two-tier distribution for their industry leading Unified Communications and Mobility Solutions. This creates a highly efficient route to market for Black Box Network Services and our ShoreTel customers through Tech Data’s best in class logistics coupled with industry-leading e-business and IT tools,” Gendron stated in the press release. “We believe Tech Data’s superior capabilities and their attention to detail will help Black Box Network Services continue to meet and exceed the expectations of our enterprise customers. Black Box Network Services Canada is happy to be partnered with ShoreTel and Tech Data, both strong partners to help delight our customers and grow our Canadian business.”
For more information visit www.shoretel.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Monday, September 19, 2011
Scorpex, Inc. (SRPX) to Grow with Mexico’s Rising Economy
Scorpex, Inc. has linked its future to Mexico and the country’s increasing importance to the United States. Scorpex is a developing company, positioning itself as a critical provider of industrial and hazardous waste handling services for the growing Baja Mexico/California region. The expanding need for waste processing in the area is made clear by the reception the fledgling company is receiving, both from the government and regional industry. The company is currently finishing its first facility near Ensenada, Baja, Mexico, and already has more business available than it can handle. Once all of the state-of-the-art processing equipment is installed and operational, and final permits are in hand, the company expects to be able to process roughly 800 tons of waste per day.
As Mexico continues to build its economic importance to the U.S., Scorpex is in line to benefit from the growing demand for adequate handling of industrial wastes brought on by increased manufacturing, export, and distribution traffic. The relatively strong recent growth of Mexican industrial output, from auto manufacturing and other areas, in spite of the current state of the American economy, is surprising to some, since the vast majority of Mexico’s exports head north to the U.S. As a buffer against any future negative impact, Mexico’s central bank is expected by some to maintain growth by reducing interest rates. Official forecasts now call for a 3.5% economic growth in 2012. Mexico’s Secretary of Finance, Ernesto Cordero, stated the most basic goal of the government’s economic strategy: “Mexico needs to keep growing and distance itself from fiscal crises in other countries.”
For Scorpex, an important development in U.S.-Mexican economic relations was the recent agreement between the two countries to remove restrictions on trucks using each other’s highways. It was a major sticking point associated with the North American Free Trade Agreement, and its resolution brings the end of high Mexican tariffs, and should stimulate growth on both sides of the border. Besides direct benefits to Scorpex, and the truck traffic it involves, there are more general long-term benefits. As industrial and other business activity rises, the need for what Scorpex offers, already very high, will no doubt increase.
For additional information on Scorpex, visit the company’s website at www.Scorpex.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
As Mexico continues to build its economic importance to the U.S., Scorpex is in line to benefit from the growing demand for adequate handling of industrial wastes brought on by increased manufacturing, export, and distribution traffic. The relatively strong recent growth of Mexican industrial output, from auto manufacturing and other areas, in spite of the current state of the American economy, is surprising to some, since the vast majority of Mexico’s exports head north to the U.S. As a buffer against any future negative impact, Mexico’s central bank is expected by some to maintain growth by reducing interest rates. Official forecasts now call for a 3.5% economic growth in 2012. Mexico’s Secretary of Finance, Ernesto Cordero, stated the most basic goal of the government’s economic strategy: “Mexico needs to keep growing and distance itself from fiscal crises in other countries.”
For Scorpex, an important development in U.S.-Mexican economic relations was the recent agreement between the two countries to remove restrictions on trucks using each other’s highways. It was a major sticking point associated with the North American Free Trade Agreement, and its resolution brings the end of high Mexican tariffs, and should stimulate growth on both sides of the border. Besides direct benefits to Scorpex, and the truck traffic it involves, there are more general long-term benefits. As industrial and other business activity rises, the need for what Scorpex offers, already very high, will no doubt increase.
For additional information on Scorpex, visit the company’s website at www.Scorpex.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The Life Saving Potential of VistaGen Therapeutics, Inc. (VSTA)
The good news is that new pharmaceutical discoveries are being made nearly every day for the treatment of life threatening diseases. The bad news is that, after hundreds of millions of dollars spent to identify and develop these potential lifesavers, they often never make it to market. Lives may hang in the balance, but it makes little difference when promising new drugs are allowed to sit on the shelf, sometimes indefinitely.
The problem is that every new drug, regardless of its potential efficacy, requires formal approval by the U.S. Food & Drug Administration. Unfortunately, over the past decade, the number of new drugs approved by the FDA has dropped by a full 50%, despite major increases in research and development by the pharmaceuticals. It’s not unusual for a company to invest more than a billion dollars, and over a decade of skilled resources, to get a new drug candidate to market. The fact is that even the most promising candidates can be shelved late in the game, long after the money and time has been spent, due to toxicity issues that were not discovered earlier. It’s a huge loss to the developing company, but a greater loss to the people whose lives could have been improved or even saved.
This is not an isolated problem. It is estimated that approximately a third of all potential new drug candidates fail to meet safety requirements in preclinical or clinical trials. The result is a massive inventory of promising drugs that are currently discontinued due to safety concerns. However, with more predictive toxicology bioassay systems, many of these hibernating drug candidates could be revised and developed, creating variants which are as effective as the original, but without the safety concerns.
VistaGen Therapeutics, Inc. provides an advanced stem-cell based biotechnology that fills that critical gap, allowing shelved drugs to be rescued and moved forward to realize their originally intended potential. The technology offers a significantly improved bioassay option for faster and less expensive drug evaluation and development, including the development of shelved drug variants. VistaGen is clear in its intention to develop a diverse drug pipeline including proprietary drug rescue variants, offering the efficacy of the original, without the toxicity issues.
It represents the possibility of unlocking billions of dollars in drug potential, currently on hold because of a lack of such technology. More importantly to many, it means the chance for rescued lives. As one VistaGen investor put it: “We are very proud to be investing in technology that holds promise for so many.”
For additional information, visit the company’s website at www.VistaGen.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The problem is that every new drug, regardless of its potential efficacy, requires formal approval by the U.S. Food & Drug Administration. Unfortunately, over the past decade, the number of new drugs approved by the FDA has dropped by a full 50%, despite major increases in research and development by the pharmaceuticals. It’s not unusual for a company to invest more than a billion dollars, and over a decade of skilled resources, to get a new drug candidate to market. The fact is that even the most promising candidates can be shelved late in the game, long after the money and time has been spent, due to toxicity issues that were not discovered earlier. It’s a huge loss to the developing company, but a greater loss to the people whose lives could have been improved or even saved.
This is not an isolated problem. It is estimated that approximately a third of all potential new drug candidates fail to meet safety requirements in preclinical or clinical trials. The result is a massive inventory of promising drugs that are currently discontinued due to safety concerns. However, with more predictive toxicology bioassay systems, many of these hibernating drug candidates could be revised and developed, creating variants which are as effective as the original, but without the safety concerns.
VistaGen Therapeutics, Inc. provides an advanced stem-cell based biotechnology that fills that critical gap, allowing shelved drugs to be rescued and moved forward to realize their originally intended potential. The technology offers a significantly improved bioassay option for faster and less expensive drug evaluation and development, including the development of shelved drug variants. VistaGen is clear in its intention to develop a diverse drug pipeline including proprietary drug rescue variants, offering the efficacy of the original, without the toxicity issues.
It represents the possibility of unlocking billions of dollars in drug potential, currently on hold because of a lack of such technology. More importantly to many, it means the chance for rescued lives. As one VistaGen investor put it: “We are very proud to be investing in technology that holds promise for so many.”
For additional information, visit the company’s website at www.VistaGen.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Pansoft Company Ltd. (PSOF) Strengthens Position in Thriving Chinese Hydrocarbon Sector with Acquisition of Top Coal Mining HR Solutions and Service Provider
Pansoft Company, one of China’s top hydrocarbon industry providers of comprehensive enterprise resource planning software solutions and various professional services, announced a further expansion move recently with the signing of a definitive agreement to acquire Hefei Langji Technology Co., Ltd. (including wholly-owned subsidiary Shanghai Zhongrui) for a reported $1.69M (RMB10.8M).
Chairman of PSOF, Hugh Wang, called the Langji move a milestone for the Company, as it follows the ITLamp Technology and HongAo Power acquisitions of 2010, cementing PSOF in the heart of China’s roaring hydrocarbon sector.
Langji has risen from is start eight years ago to become the Chinese coal-mining industry’s top HR solutions provider. The big, state-owned coal mining groups which make up much of the industry in China have come to rely on the sophisticated HR management solutions Langji is known for. With a staff of some 40 people, Langji pulled down audited revenue of $1M in 2010 ($0.26M net income) and did brisk business through its Shanghai subsidiary, Zhongrui (which will be maintained to focus on small, to mid-sized companies in parallel industries).
Wang noted the solid footprint Langji has in the coal sector and spoke of the respect its HR solutions have won across the spectrum of clients, touting the significance of the acquisition for boosting PSOF’s already commanding penetration into the Chinese hydrocarbon industry as a whole. Wang asserted that the ability to leverage Langji’s customer base, in order to expand the Company’s footprint in the coal mining sector, in conjunction with the core proprietary technologies acquired (like HR solutions engineered specifically for the coal mining industry), would also accelerate the expansion process.
The service/solution platform thus realized certainly will be second-to-none and Pansoft will be able to exploit the Zhongrui Shanghai office to fully target the abundance of this heavily industrial region. It really looks like Pansoft is making all the right moves in order to dominate significant territory in the Chinese hydrocarbon area.
Terms of the deal call for four installments, the first of which (35% of the total) is to be paid in combined cash and PSOF common stock, with the remaining installments paid annually over three years via the same combination of cash and stock (all payments subject to the achievement of revenue targets by the acquired entities). Part of the consideration for the deal will be paid via Pansoft’s share repurchasing activities on the open market (157k shares purchased as of Sept. 15, 2011), as approved by the Company’s board (in accordance with Rule 10b5-18).
Wang emphasized that this important strategic move by the Company would offer an ideal position for long-term growth in the next logical area, coal mining. Calling Langji an excellent fit for the Company’s existing competencies/structure, and pledged an expedient integration into the overall company architecture.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Chairman of PSOF, Hugh Wang, called the Langji move a milestone for the Company, as it follows the ITLamp Technology and HongAo Power acquisitions of 2010, cementing PSOF in the heart of China’s roaring hydrocarbon sector.
Langji has risen from is start eight years ago to become the Chinese coal-mining industry’s top HR solutions provider. The big, state-owned coal mining groups which make up much of the industry in China have come to rely on the sophisticated HR management solutions Langji is known for. With a staff of some 40 people, Langji pulled down audited revenue of $1M in 2010 ($0.26M net income) and did brisk business through its Shanghai subsidiary, Zhongrui (which will be maintained to focus on small, to mid-sized companies in parallel industries).
Wang noted the solid footprint Langji has in the coal sector and spoke of the respect its HR solutions have won across the spectrum of clients, touting the significance of the acquisition for boosting PSOF’s already commanding penetration into the Chinese hydrocarbon industry as a whole. Wang asserted that the ability to leverage Langji’s customer base, in order to expand the Company’s footprint in the coal mining sector, in conjunction with the core proprietary technologies acquired (like HR solutions engineered specifically for the coal mining industry), would also accelerate the expansion process.
The service/solution platform thus realized certainly will be second-to-none and Pansoft will be able to exploit the Zhongrui Shanghai office to fully target the abundance of this heavily industrial region. It really looks like Pansoft is making all the right moves in order to dominate significant territory in the Chinese hydrocarbon area.
Terms of the deal call for four installments, the first of which (35% of the total) is to be paid in combined cash and PSOF common stock, with the remaining installments paid annually over three years via the same combination of cash and stock (all payments subject to the achievement of revenue targets by the acquired entities). Part of the consideration for the deal will be paid via Pansoft’s share repurchasing activities on the open market (157k shares purchased as of Sept. 15, 2011), as approved by the Company’s board (in accordance with Rule 10b5-18).
Wang emphasized that this important strategic move by the Company would offer an ideal position for long-term growth in the next logical area, coal mining. Calling Langji an excellent fit for the Company’s existing competencies/structure, and pledged an expedient integration into the overall company architecture.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Natus Medical Inc. (BABY) Acquires Embla to Become Worldwide Leader in Sleep Apnea Diagnostics
Natus Medical, a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders, recently announced the acquisition of Embla Systems, the largest company focused solely on sleep diagnostics. Since the mid-1990′s, Elma Systems has been developing innovative products to assist sleep labs in the diagnosis of sleep apnea, a sleep disorder that causes abnormally low breathing during sleep. Internationally, Embla is also the leader in devices used for sleep studies in patient’s homes. Embla reported earnings of approximately $30 million for its fiscal year that ended in December 2010.
Natus acquired the shares of Embla for $16.1 million in cash and expects the acquisition will be accretive to earnings in 2012, adding $0.08 to the non-GAAP earnings per share for the year. Natus funded the acquisition with available cash on hand. The company expects that the new company will make Natus number one in the worldwide sleep diagnostic market with annual revenue approaching $35 million.
“Additionally, with approximately 40% of Embla’s revenue coming from international markets, this acquisition positions Natus as the leader in sleep diagnostics outside the United States,” said Jim Hawkins, Chief Executive Officer, Natus in a press release on Friday. “More than 100 million people worldwide are suspected to have obstructive sleep apnea. Because of lack of awareness among both patients and physicians more than 80% of those affected remain undiagnosed.”
In the United States, one in every 15 American is affected by some form of sleep apnea. One study showed that 9% of women and 24% of men has undiagnosed and untreated sleep apnea, and thus were in jeopardy of having coronary artery disease, congestive heart failure, hypertension, pulmonary hypertension, stroke and clinical depression.
Embla partners with sleep businesses to provide sleep sensors and products like the Embletta Gold portable sleep testing device, the Enterprise Sleep Business Management System and three PSG or sleep study platforms which provide tools to optimize the efficiency of sleep labs. Embla has offices in Denver and Buffalo as well as worldwide in Canada, the Netherlands and Germany.
More Information on Natus, Medical can be found at www.natus.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Natus acquired the shares of Embla for $16.1 million in cash and expects the acquisition will be accretive to earnings in 2012, adding $0.08 to the non-GAAP earnings per share for the year. Natus funded the acquisition with available cash on hand. The company expects that the new company will make Natus number one in the worldwide sleep diagnostic market with annual revenue approaching $35 million.
“Additionally, with approximately 40% of Embla’s revenue coming from international markets, this acquisition positions Natus as the leader in sleep diagnostics outside the United States,” said Jim Hawkins, Chief Executive Officer, Natus in a press release on Friday. “More than 100 million people worldwide are suspected to have obstructive sleep apnea. Because of lack of awareness among both patients and physicians more than 80% of those affected remain undiagnosed.”
In the United States, one in every 15 American is affected by some form of sleep apnea. One study showed that 9% of women and 24% of men has undiagnosed and untreated sleep apnea, and thus were in jeopardy of having coronary artery disease, congestive heart failure, hypertension, pulmonary hypertension, stroke and clinical depression.
Embla partners with sleep businesses to provide sleep sensors and products like the Embletta Gold portable sleep testing device, the Enterprise Sleep Business Management System and three PSG or sleep study platforms which provide tools to optimize the efficiency of sleep labs. Embla has offices in Denver and Buffalo as well as worldwide in Canada, the Netherlands and Germany.
More Information on Natus, Medical can be found at www.natus.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Friday, September 16, 2011
Asia Pacific Wire & Cable (APWC) Reports Solid Q2, HY 2011 Results
Asia Pacific Wire & Cable, manufacturer of telecommunications products in the Asia Pacific region, today reported strong, unaudited consolidated results for the second quarter and first half ended June 30, 2011.
For the second quarter of 2011, APWC reported revenues of $148.7 million, up 40 percent compared to $106.0 million reported in the comparable quarter of 2010.
Gross profit increased 15 percent to $16.4 million compared to $14.2 million reported in the second quarter of 2010.
The company reported net income attributable to APWC shareholders at $2.4 million, or $0.17 per share, compared with $3.7 million, or $0.27 per share, in the same period a year ago.
Operating income decreased 1.6 percent to $6.8 million compared to the $7.0 million reported in the year-ago quarter.
For the first half of 2011, APWC reported revenues of $270.5 million, a 28 percent increase over the first six months of 2010.
Gross profit was $29.3 million in the first half, up 14 percent from $25.6 million reported in the first half of last year.
Operating income in the first half increased 4.5 percent to $12.7 million compared to $12.2 million in the year-ago period.
The company reported net income attributable to APWC shareholders for the first half of 2011 was $5.1 million, or $0.37 per share, compared to $7.4 million, or $0.54 per share, in the year-ago period.
As of June 30, 2011, APWC reported $75.5 million in cash and cash equivalents, and $1.0 million in unrestricted short-term bank deposits, totaling $76.5 million, compared to cash and equivalents of $63.2 million as of December 31, 2010. The company reported total current assets of $370.2 million as of June 30, 2011, compared to $329.5 million at the end of 2010; total current liabilities were $191.2 million as of June 30, 2011, compared to $158.8 million at the end of 2010.
For more information visit www.apwcc.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
For the second quarter of 2011, APWC reported revenues of $148.7 million, up 40 percent compared to $106.0 million reported in the comparable quarter of 2010.
Gross profit increased 15 percent to $16.4 million compared to $14.2 million reported in the second quarter of 2010.
The company reported net income attributable to APWC shareholders at $2.4 million, or $0.17 per share, compared with $3.7 million, or $0.27 per share, in the same period a year ago.
Operating income decreased 1.6 percent to $6.8 million compared to the $7.0 million reported in the year-ago quarter.
For the first half of 2011, APWC reported revenues of $270.5 million, a 28 percent increase over the first six months of 2010.
Gross profit was $29.3 million in the first half, up 14 percent from $25.6 million reported in the first half of last year.
Operating income in the first half increased 4.5 percent to $12.7 million compared to $12.2 million in the year-ago period.
The company reported net income attributable to APWC shareholders for the first half of 2011 was $5.1 million, or $0.37 per share, compared to $7.4 million, or $0.54 per share, in the year-ago period.
As of June 30, 2011, APWC reported $75.5 million in cash and cash equivalents, and $1.0 million in unrestricted short-term bank deposits, totaling $76.5 million, compared to cash and equivalents of $63.2 million as of December 31, 2010. The company reported total current assets of $370.2 million as of June 30, 2011, compared to $329.5 million at the end of 2010; total current liabilities were $191.2 million as of June 30, 2011, compared to $158.8 million at the end of 2010.
For more information visit www.apwcc.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
BSD Medical Corp. (BSDM) Increases Interest in Ablation Treatment MicroThermX (R) as Therapy for Cancer at European Medical Conference
BSD Medical Corp., a leading provider of medical systems that utilize heat therapy to treat cancer, announced that the MicroThermX (R) Microwave Ablation System is continuing to receive positive feedback in medical conventions across the world. At the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) annual meeting held September 10-14 in Munich, Germany, the MicroThermX (R) system was showcased in the CIRSE exhibit space for over 5,000 clinicians from 70 countries in the field of interventional radiology. A BSD ablation engineer revealed that the microwave antennas used in this product can sharply decrease the danger of skin burn as compared to other asynchronous ablations.
The MicroThermX(R) Microwave Ablation System uses an innovative compact design of a microwave generator, single-patient-use disposable antennas and a thermistor-based temperature monitoring system to deliver high power levels of ablation during a single procedure. The MicroThermX(R) utilizes innovative synchronous phased array technology that was developed and patented by BSD. The global market potential for soft tissue ablation has been estimated to exceed $2.3 billion, offering a significant opportunity for BSD Medical.
“The CIRSE meeting was effectively used to further develop the Company’s association with international key opinion leaders, many of whom requested demonstrations of the MicroThermX(R),” stated Steven Smith, VP for Marketing and Business Development for BSD in a press release on Thursday. “The increasing clinical interest in the MicroThermX(R) was evident by a constant stream of interested clinicians and medical distributors from around the world.”
Microwave ablation is the most recent development in the field of tumor ablation and allows for a flexible approach to tumor treatment that uses imaging guidance to localize the tumor for placement of a thin microwave antenna directly into the tumor. The microwave generator emits an electromagnetic wave that agitates water molecules in the surrounding tissue, producing friction and heat, thus killing the cells. The main advantages of the microwave technology include larger tumor ablation volumes, faster ablation times and an improved convection profile. Microwave ablation has promising potential in the treatment of primary and secondary liver disease, primary and secondary lung malignancies, renal and adrenal tumors, and bone metastases.
For more information on BSD Medical, please visit www.BSDMedical.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The MicroThermX(R) Microwave Ablation System uses an innovative compact design of a microwave generator, single-patient-use disposable antennas and a thermistor-based temperature monitoring system to deliver high power levels of ablation during a single procedure. The MicroThermX(R) utilizes innovative synchronous phased array technology that was developed and patented by BSD. The global market potential for soft tissue ablation has been estimated to exceed $2.3 billion, offering a significant opportunity for BSD Medical.
“The CIRSE meeting was effectively used to further develop the Company’s association with international key opinion leaders, many of whom requested demonstrations of the MicroThermX(R),” stated Steven Smith, VP for Marketing and Business Development for BSD in a press release on Thursday. “The increasing clinical interest in the MicroThermX(R) was evident by a constant stream of interested clinicians and medical distributors from around the world.”
Microwave ablation is the most recent development in the field of tumor ablation and allows for a flexible approach to tumor treatment that uses imaging guidance to localize the tumor for placement of a thin microwave antenna directly into the tumor. The microwave generator emits an electromagnetic wave that agitates water molecules in the surrounding tissue, producing friction and heat, thus killing the cells. The main advantages of the microwave technology include larger tumor ablation volumes, faster ablation times and an improved convection profile. Microwave ablation has promising potential in the treatment of primary and secondary liver disease, primary and secondary lung malignancies, renal and adrenal tumors, and bone metastases.
For more information on BSD Medical, please visit www.BSDMedical.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Thursday, September 15, 2011
STAAR Surgical Co. (STAA) Updates on Product Launch, Participation in 2011 Congress of European Society of Cataract and Refractive Surgeons
STAAR Surgical Company, a leading developer of minimally invasive ophthalmic products, today detailed is activities scheduled before and during the 2011 Congress of European Society of Cataract and Refractive Surgeons (ESCRS) this weekend, during which the company will officially launch two key products in Europe and other countries that accept CE Mark approvals.
The Congress will be held in Vienna, Austria, September 17 through 21, 2011. STAAR will launch its Visian Implantable Collamer® Lens (ICL) with CentraFLOW™ technology, which utilizes the KS-AquaPORT™, and the nanoFLEX™ IOL, both of which the company received CE Mark approval for in April 2011.
Beginning tomorrow, STAAR will hold its 8th Annual Visian ICL Experts Symposium. The company said it anticipates more than 100 surgeons from 34 countries to attend the “by invitation only” roundtable discussion sessions on the Visian ICL technology.
Hans Blickensdoerfer, president of Europe and Latin America for STAAR, said the meeting not only represents the official unveiling of its key products, but is also a celebration of a recent significant achievement.
“We anticipate this will be the most exciting and productive ESCRS meeting in our history,” Blickensdoerfer stated in the press release. “We will be celebrating the key milestone of over a quarter of a million successful Visian ICL implants at the same time we are introducing the new Visian ICL with CentraFLOW technology.”
Blickensdoerfer said that over its 15-year history with Visian ICL, it has become the fastest growing refractive technology in the world.
“Now, for the first time in our history, the Visian ICL can treat all LASIK eligible patients and more, while the procedure is as convenient for both the patient and surgeon, if not more so, than LASIK. In other words, we are now on at least an equal playing level with LASIK and we believe with even better visual results for the patient,” he stated.
The ESCRS Congress official program begins Saturday and will include more than 50 presentations in which the Visian ICL technology will be presented.
On Monday, STAAR will host the ESCRS Lunch Symposium entitled, “Revolutions in Refractive Surgery,” which is expected to draw up to 400 surgeons. The luncheon will include six presentations by surgeons from six different countries detailing their experience with the Visian ICL technology, including the new Visian ICL with CentraFLOW technology.
For more information visit www.staar.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The Congress will be held in Vienna, Austria, September 17 through 21, 2011. STAAR will launch its Visian Implantable Collamer® Lens (ICL) with CentraFLOW™ technology, which utilizes the KS-AquaPORT™, and the nanoFLEX™ IOL, both of which the company received CE Mark approval for in April 2011.
Beginning tomorrow, STAAR will hold its 8th Annual Visian ICL Experts Symposium. The company said it anticipates more than 100 surgeons from 34 countries to attend the “by invitation only” roundtable discussion sessions on the Visian ICL technology.
Hans Blickensdoerfer, president of Europe and Latin America for STAAR, said the meeting not only represents the official unveiling of its key products, but is also a celebration of a recent significant achievement.
“We anticipate this will be the most exciting and productive ESCRS meeting in our history,” Blickensdoerfer stated in the press release. “We will be celebrating the key milestone of over a quarter of a million successful Visian ICL implants at the same time we are introducing the new Visian ICL with CentraFLOW technology.”
Blickensdoerfer said that over its 15-year history with Visian ICL, it has become the fastest growing refractive technology in the world.
“Now, for the first time in our history, the Visian ICL can treat all LASIK eligible patients and more, while the procedure is as convenient for both the patient and surgeon, if not more so, than LASIK. In other words, we are now on at least an equal playing level with LASIK and we believe with even better visual results for the patient,” he stated.
The ESCRS Congress official program begins Saturday and will include more than 50 presentations in which the Visian ICL technology will be presented.
On Monday, STAAR will host the ESCRS Lunch Symposium entitled, “Revolutions in Refractive Surgery,” which is expected to draw up to 400 surgeons. The luncheon will include six presentations by surgeons from six different countries detailing their experience with the Visian ICL technology, including the new Visian ICL with CentraFLOW technology.
For more information visit www.staar.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Procera Networks, Inc. (PKT) Announces $6 Million Second Follow-On Order with Leading North American Company
Located in Fremont, California, Procera Networks has quickly earned a reputation as a leader in the development of Intelligent Policy Enforcement (IPE) solutions. Yesterday, Procera took a major step towards prominence with the announcement they have received a $6 million second follow-on order from a leading North American Cable MSO.
This order comes just six months after the MSO awarded a $2 million follow-on order in April 2011. Procera’s PacketLogic technology is being deployed in all of the MSO’s geographies; replacing a leading competitor and symbolizing further growth for the young company as it expand its footprint and continues competitive replacement.
One of the leaders at Procera is Cam Cullen whom serves as the company’s Vice President of Global Marketing. In reference to the follow-on order, Cullen stated, “MSO’s need to understand what type of traffic and applications are driving network usage. They require reliable and detailed analytics that they can use to formulate new service plans and target demographics. Our reporting on video usage, quality of experience and popularity of content providers is priceless when growth forecasts for capital expenditures require detailed information quickly.”
Cullen further stated, “Our Intelligent Policy Enforcement Solutions enable operators to charge according to services, not just consumption, and to create innovative new services that are personalized according to what subscribers want.”
To learn more about the company as a whole, visit their corporate website at: www.proceranetworks.com.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
This order comes just six months after the MSO awarded a $2 million follow-on order in April 2011. Procera’s PacketLogic technology is being deployed in all of the MSO’s geographies; replacing a leading competitor and symbolizing further growth for the young company as it expand its footprint and continues competitive replacement.
One of the leaders at Procera is Cam Cullen whom serves as the company’s Vice President of Global Marketing. In reference to the follow-on order, Cullen stated, “MSO’s need to understand what type of traffic and applications are driving network usage. They require reliable and detailed analytics that they can use to formulate new service plans and target demographics. Our reporting on video usage, quality of experience and popularity of content providers is priceless when growth forecasts for capital expenditures require detailed information quickly.”
Cullen further stated, “Our Intelligent Policy Enforcement Solutions enable operators to charge according to services, not just consumption, and to create innovative new services that are personalized according to what subscribers want.”
To learn more about the company as a whole, visit their corporate website at: www.proceranetworks.com.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
China Botanic Pharmaceutical (CBP) Posts Strong Q3 Results, Guidance
China Botanic Pharmaceutical Inc., a biopharmaceutical and botanical products developer in the People’s Republic of China, today announced financial results for the three months ended July 31, 2011, reflecting increases across the board.
Third quarter net sales increased 33.6 percent to $12.4 million compared to $9.3 million during the same period in 2010. The company attributes the increase mainly to a year-over-year increase in average selling prices of the company’s products.
Net income for the third quarter of 2011 rose 73.0 percent to $2.5 million, or $0.07 per diluted share.
Gross profit increased 60.8 percent to $7.5 million compared to $4.6 million in the third quarter of fiscal 2010. Gross margin increased to 60.3 percent as compared to 50.1 percent in the comparable quarter of 2010. Price increases in all the company’s products countered modest increases in raw material prices and fueled growth in gross profit.
Operating expenses for the third quarter of fiscal 2011 were $4.5 million, as compared to $3.2 million in the same period last year. Operating income in the third quarter of 2011 was $3.0 million compared to $1.4 million in the third quarter of 2010. Operating margin increased year-over-year to 24.1 percent from 15.5 percent.
“We are pleased to report double-digit revenue and net income growth in the third quarter of fiscal year 2011. Our strong growth in sales, profitability, and operating cash flow during the quarter was largely driven by increase in our average selling prices and four new products introduced in the fourth quarter of fiscal year 2010,” Shaoming Li, chairman and CEO of China Botanic stated in the press release.
Li also highlighted strong sales of the company’s Siberian Ginseng products, which accounted for 50 percent of total third-quarter 2011 revenue.
As of July 31, 2011, the company had cash and cash equivalents of approximately $38.3 million; total current assets of approximately $58.9 million; working capital of approximately $45.8 million as compared to $47.1 million for the fiscal year ended October 31, 2010; and no long-term debt on its balance sheet as of July 31, 2011.
Moving forward, China Botanical will pay special attention to several products that it believes will contribute to the company meeting its 2011 guidance, as well as to its Ah City project.
“We will continue to focus on our botanical anti depression and nerve regulations products, and continue to invest in research and development of these products,” Li stated. “We remain confident that we will meet our fiscal year 2011 guidance for revenue in the range of $70.6 million and $71.7 million and net income of $25.5 million. We have completed the architectural design of our Ah City phase two project and are in the process of obtaining approval from relevant government authorities. and expect to begin construction following receipt of approval documents. The Ah City phase two project is expected to be completed in the end of 2012. In the longer term, we expect Ah City natural and pharmaceutical plant expansion and new products which are currently in our R&D pipeline will provide sizeable contribution to our future revenue and net income growth.”
For more information visit www.renhuang.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Third quarter net sales increased 33.6 percent to $12.4 million compared to $9.3 million during the same period in 2010. The company attributes the increase mainly to a year-over-year increase in average selling prices of the company’s products.
Net income for the third quarter of 2011 rose 73.0 percent to $2.5 million, or $0.07 per diluted share.
Gross profit increased 60.8 percent to $7.5 million compared to $4.6 million in the third quarter of fiscal 2010. Gross margin increased to 60.3 percent as compared to 50.1 percent in the comparable quarter of 2010. Price increases in all the company’s products countered modest increases in raw material prices and fueled growth in gross profit.
Operating expenses for the third quarter of fiscal 2011 were $4.5 million, as compared to $3.2 million in the same period last year. Operating income in the third quarter of 2011 was $3.0 million compared to $1.4 million in the third quarter of 2010. Operating margin increased year-over-year to 24.1 percent from 15.5 percent.
“We are pleased to report double-digit revenue and net income growth in the third quarter of fiscal year 2011. Our strong growth in sales, profitability, and operating cash flow during the quarter was largely driven by increase in our average selling prices and four new products introduced in the fourth quarter of fiscal year 2010,” Shaoming Li, chairman and CEO of China Botanic stated in the press release.
Li also highlighted strong sales of the company’s Siberian Ginseng products, which accounted for 50 percent of total third-quarter 2011 revenue.
As of July 31, 2011, the company had cash and cash equivalents of approximately $38.3 million; total current assets of approximately $58.9 million; working capital of approximately $45.8 million as compared to $47.1 million for the fiscal year ended October 31, 2010; and no long-term debt on its balance sheet as of July 31, 2011.
Moving forward, China Botanical will pay special attention to several products that it believes will contribute to the company meeting its 2011 guidance, as well as to its Ah City project.
“We will continue to focus on our botanical anti depression and nerve regulations products, and continue to invest in research and development of these products,” Li stated. “We remain confident that we will meet our fiscal year 2011 guidance for revenue in the range of $70.6 million and $71.7 million and net income of $25.5 million. We have completed the architectural design of our Ah City phase two project and are in the process of obtaining approval from relevant government authorities. and expect to begin construction following receipt of approval documents. The Ah City phase two project is expected to be completed in the end of 2012. In the longer term, we expect Ah City natural and pharmaceutical plant expansion and new products which are currently in our R&D pipeline will provide sizeable contribution to our future revenue and net income growth.”
For more information visit www.renhuang.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Subscribe to:
Posts (Atom)